Skip to main content
Journal of Clinical Medicine logoLink to Journal of Clinical Medicine
. 2025 Oct 29;14(21):7691. doi: 10.3390/jcm14217691

Long-Term and Heavy Smoking as a Risk Factor for Lumbar Spinal Stenosis: Evidence from a Large-Scale, Nationwide Population-Based Cohort

Ji-Hyun Ryu 1, Ki-Won Kim 1,*, Ju-Yeong Kim 2,*
Editor: Seong-Eun Byun
PMCID: PMC12608443  PMID: 41227087

Abstract

Background and Objectives: Lumbar spinal stenosis (LSS) is a leading cause of disability in older adults, but the role of cigarette smoking in its development remains unclear. This study aimed to clarify the association between smoking and the incidence of LSS, with a focus on dose–response relationships and subgroup variations by age and sex. Methods: We conducted a nationwide, population-based cohort study using the Korean National Health Insurance Service database. A total of 2,123,268 adults aged ≥ 40 years who underwent health screening in 2009 were followed until LSS diagnosis, death, or 2020. Smoking status, duration, daily consumption, and pack-years were assessed. Cox proportional hazards models with progressive adjustment for demographic, lifestyle, and clinical factors were applied. Results: Over a mean follow-up of 8.2 years (17.5 million person-years), 721,909 new cases of LSS were identified. Fully adjusted models showed higher risk in former (HR 1.047; 95% CI, 1.039–1.056) and current smokers (HR 1.052; 95% CI, 1.044–1.060) compared with never smokers. A clear dose–response pattern was observed, with the greatest risk in heavy smokers (≥40 pack-years; HR 1.207; 95% CI, 1.191–1.222). Subgroup analyses indicated stronger associations among adults aged ≥ 65 years and in women. Conclusions: Cigarette smoking was independently associated with an increased risk of LSS, with risk increasing according to lifetime exposure. The findings underscore the importance of smoking cessation strategies to reduce the burden of spinal degeneration, especially in older adults and women.

Keywords: lumbar spinal stenosis, cigarette smoking, cohort study, pack-years, age, sex

1. Introduction

Lumbar spinal stenosis (LSS), a prevalent degenerative disorder of the spine, is characterized by abnormal narrowing of the spinal canal, resulting in compression of the nerve roots or spinal cord. This condition leads to chronic pain, neurological deficits, and functional disability, thereby substantially impairing patients’ quality of life [1,2]. Globally, LSS ranks among the leading causes of disability in older adults, imposing substantial healthcare costs and contributing to productivity loss. The prevalence of symptomatic LSS is estimated at approximately 8–11% in the general population aged over 60 years [3], and this burden is expected to grow rapidly in aging societies. In particular, Korea is experiencing rapid population aging; the proportion of the population aged ≥65 years is projected to exceed 20% by 2025, further amplifying the clinical and economic impact of LSS [4]. This demographic shift underscores the importance of identifying modifiable risk factors to mitigate the future burden of the disease.

The etiology of LSS can be congenital or acquired, with the latter—most often driven by degenerative changes—being more prevalent in older adults. Multiple factors have been implicated in disease onset and progression, including age, abnormal mechanical loading, genetic predisposition, metabolic syndrome, psychological stress, and physical inactivity [5]. Smoking, a well-established and preventable health hazard, is conclusively linked to cardiovascular disease, malignancy, and chronic respiratory disorders [6]. Emerging evidence also indicates that smoking adversely affects the musculoskeletal system, contributing to intervertebral disk degeneration and accelerated LSS [7]. The proposed biological mechanisms include nicotine-induced vasoconstriction, atherosclerotic changes in the spinal microvasculature, impaired collagen synthesis, reduced nutrient diffusion into the intervertebral disks, and chronic inflammation—all of which may exacerbate degenerative processes in the spine [8,9].

Several observational studies have explored the association between smoking and LSS [10]. However, the exact causal relationship remains unclear [11], as most prior investigations have been limited by small sample sizes, non-representative populations, short follow-up periods, and insufficient adjustment for potential confounders. Furthermore, few studies have examined dose–response relationships using detailed smoking exposure metrics—such as duration, intensity, and cumulative pack-years—or assessed whether these associations vary by age or sex. These gaps in the literature hinder robust causal inference and limit the development of targeted prevention strategies.

Given the high prevalence of both smoking and LSS, elucidating their relationship holds substantial clinical and public health relevance. Leveraging the Korean National Health Insurance Service (NHIS) database—which includes virtually the entire adult population and provides comprehensive health screening and claims data—we conducted a large-scale, nationwide, population-based cohort study. The unique strengths of this study include its nationally representative sample, long-term follow-up, precise classification of smoking exposure, and detailed stratified analyses by demographic and clinical characteristics. This study aimed to investigate the association between smoking and the risk of LSS, focusing on dose–response relationships and exploring whether these associations differ by age and sex.

2. Methods

2.1. Data Source and Study Population

We utilized the health screening and claims data from the Korean National Health Insurance Service (NHIS), a universal, single-payer system operated by the South Korean government. Nearly all Korean citizens are enrolled, and adults aged 40 years or older are eligible for biennial national health screenings. For this study, we included individuals aged ≥ 40 years who underwent health screening in 2009.

The health screening data include lifestyle factors, anthropometric measurements, laboratory test results, and questionnaire responses. The claims data provide diagnostic and treatment records based on the International Classification of Diseases, 10th Revision (ICD-10).

Initially, 4,234,415 individuals underwent health screening in 2009. After excluding 1,338,032 individuals aged < 40 years, 2,896,383 subjects remained. We further excluded 536,893 individuals with a prior diagnosis of LSS (ICD-10 codes M48.06) before 2009. Another 150,370 individuals with missing data on key variables, including smoking status, were excluded. To minimize the risk of reverse causality, 85,852 participants diagnosed with LSS within one year of their screening date were also excluded. Ultimately, a total of 2,123,268 individuals were included in the final cohort (Figure 1).

Figure 1.

Figure 1

Flow chart of cohort selection.

Incident lumbar spinal stenosis (LSS) was defined as having at least three separate medical claims with the ICD-10 code M48.06 on different dates. In the Korean National Health Insurance system, a diagnostic code must accompany any reimbursed clinical service, including outpatient consultations, diagnostic imaging, medication prescriptions, spinal injections or procedures, and surgical admissions. Each claim was issued by a board-certified orthopedic or neurosurgical specialist. Therefore, these claims represent comprehensive medical encounters for the diagnosis and treatment of LSS, ensuring high diagnostic validity. This rule was applied throughout the entire post-baseline follow-up without an upper bound on the interval between the first and third claim. This approach captures clinically relevant cases that have been thoroughly evaluated and deemed to require medical attention, rather than isolated radiographic findings. Participants were followed from the date of health screening until the date of LSS diagnosis, death, or 31 December 2020, whichever came first.

2.2. Ethics

This study was approved by the Institutional Review Board (IRB) of The Catholic University of Korea. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The NHIS database was accessed with official permission, and all data were de-identified. Therefore, informed consent was not required.

2.3. Health Screening Variables and Definition of Comorbidities

Health screening data included self-reported lifestyle factors (e.g., smoking, alcohol consumption, physical activity, and income level), anthropometric measurements (e.g., height, weight, waist circumference, and blood pressure), and laboratory tests (e.g., fasting glucose, total cholesterol, HDL-C, LDL-C, and triglycerides). For the purpose of this study, smoking exposure was classified based on self-reported data from the 2009 health screening. Smoking status was categorized as never, former, or current smokers. For former and current smokers, additional variables were collected: smoking duration (in years), number of cigarettes smoked per day, and cumulative smoking exposure (calculated as pack-years). Pack-years were calculated by multiplying the number of packs of cigarettes smoked per day (1 pack = 20 cigarettes) by the number of years the person smoked. These smoking variables, including duration and daily amount, were obtained through standardized self-reported questionnaires administered as part of the NHIS health screening program. These detailed metrics were used to assess dose–response relationships.

Height and weight were measured with shoes off and light clothing, respectively. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Blood samples were obtained after at least 8 h of fasting.

Comorbidities were defined as follows:

  • Hypertension: Presence of ICD-10 codes I10–I13 or I15 along with prescription of antihypertensive medication, or a systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg at screening.

  • Diabetes mellitus: Presence of ICD-10 codes E11–E14 along with prescription of antidiabetic medication, or a fasting glucose level ≥ 126 mg/dL.

  • Dyslipidemia: Presence of ICD-10 code E78, prescription of lipid-lowering agents, or a total cholesterol level ≥ 240 mg/dL.

These definitions were consistent with the prevalence rates presented in the comparison table of smoking status groups. All major comorbidity indicators were confirmed using both anthropometric and biochemical data, ensuring completeness of the dataset.

2.4. Statistical Analysis

2.4.1. Basic Statistical Analysis

Baseline characteristics of participants were summarized by smoking status (never, former, and current smokers). Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables as number (n) and percentage (%). Group comparisons were performed using one-way analysis of variance (ANOVA) for continuous variables and the chi-square test for categorical variables. Triglycerides, which did not follow a normal distribution, were reported as median and interquartile range (IQR). All statistical analyses were conducted using two-sided tests, and a p-value < 0.05 was considered statistically significant.

The incidence rate (IR) of LSS was calculated as the number of events divided by total person-years of follow-up and presented per 1000 person-years. The association between smoking and the risk of LSS was evaluated using the Cox proportional hazards model. Four models with progressive adjustment for potential confounders were constructed: Model 1: Unadjusted, Model 2: Adjusted for age and sex, Model 3: Model 2 + income level, body mass index (BMI), alcohol consumption, and regular physical activity, Model 4: Model 3 + diabetes mellitus, hypertension, and dyslipidemia. We examined the association between LSS and each smoking exposure variable (smoking status, smoking duration, daily cigarette consumption, and pack-years) using Cox models. We also analyzed combined metrics of smoking status with each exposure (duration, amount, pack-years) to assess whether cumulative smoking burden outweighs current status in determining risk.

In all analyses, never smokers served as the reference group, and the primary interpretation was based on Model 4. Covariate adjustment was prespecified a priori based on clinical and epidemiologic considerations to reduce confounding. Model 4 adjusted for age, sex, household income (quartiles), body mass index, alcohol intake, regular physical activity, diabetes mellitus, hypertension, and dyslipidemia. The covariate set and model sequence were pre-specified before analysis. These variables capture socioeconomic status and major lifestyle/metabolic risk factors that could influence both smoking behavior and LSS risk, and the covariate set (Models 1–4) was pre-specified before analysis.

All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA), with two-sided p-values and statistical significance set at p < 0.05. Visualizations of the results were generated using Python 3.10.18 and the matplotlib library version 3.10.0. The proportional hazards assumption was formally tested for all Cox models using Schoenfeld residuals, and no violations were observed. To evaluate potential multicollinearity among smoking-related variables, variance inflation factors (VIFs) were calculated, all of which were below 5.

2.4.2. Sex- and Age-Stratified Analyses

Subgroup analyses were conducted to assess whether the associations between smoking exposures and the risk of LSS differed by age group and sex.

We performed stratified analyses by sex and age to examine effect modification. In addition to using a dichotomized age group (40–64 vs. ≥65 years), we also conducted analyses by finer age strata (in 10-year bands), which showed similar trends (Table A2 and Table A5 and Figure A1 and Figure A3). We likewise stratified the dose–response analyses by age and sex to evaluate differences across demographic subgroups.

For these analyses, Subgroup-specific HRs and 95% CIs were estimated using Cox proportional hazards models (Model 4).

2.4.3. Multivariable Subgroup Analysis

To further investigate potential effect modification by demographic and clinical factors, subgroup analyses were performed. The subgroup variables included age (40–64 vs. ≥65 years), sex, income level (low [Q1] vs. middle-to-high [Q2–Q4]), BMI (≥25 kg/m2), abdominal obesity (waist circumference ≥ 90 cm for men, ≥85 cm for women), heavy drinking, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. Within each subgroup, the association between smoking status (former and current vs. never) and risk of LSS was estimated using Model 4. Interaction was assessed by including cross-product terms between smoking status and subgroup variables in the model, and p-values for interaction were estimated. All subgroup analyses used the fully adjusted model (Model 4).

3. Results

3.1. Baseline Characteristics of the Study Population

Among the 2,123,268 participants, 1,306,249 (61.5%) were never smokers, 339,915 (16.0%) were former smokers, and 477,104 (22.5%) were current smokers. All baseline characteristics differed significantly across the three groups (p < 0.0001), as summarized in Table 1.

Table 1.

Baseline characteristics of study participants according to smoking status.

Never Smoker Former Smoker Current Smoker p-Value
n 1,306,249 339,915 477,104
Age groups <0.0001
40–64 1,099,107 (84.14) 289,693 (85.23) 432,328 (90.62)
≥65 207,142 (15.86) 50,222 (14.77) 44,776 (9.38)
Sex <0.0001
Male 357,217 (27.35) 328,631 (96.68) 449,310 (94.17)
Female 949,032 (72.65) 11,284 (3.32) 27,794 (5.83)
Income, Lowest Q1 293,799 (22.49) 49,967 (14.7) 87,388 (18.32) <0.0001
BMI Level <0.0001
<18.5 31,271 (2.39) 4627 (1.36) 14,090 (2.95)
<23 517,639 (39.63) 97,415 (28.66) 176,102 (36.91)
<25 339,453 (25.99) 99,144 (29.17) 125,576 (26.32)
<30 375,050 (28.71) 128,663 (37.85) 148,090 (31.04)
≥30 42,836 (3.28) 10,066 (2.96) 13,246 (2.78)
Alcohol consumption <0.0001
None 954,210 (73.05) 106,525 (31.34) 122,164 (25.61)
Moderate 319,827 (24.48) 187,678 (55.21) 266,570 (55.87)
Heavy 32,212 (2.47) 45,712 (13.45) 88,370 (18.52)
Regular exercise 249,562 (19.11) 92,889 (27.33) 86,231 (18.07) <0.0001
Diabetes mellitus 123,399 (9.45) 46,555 (13.7) 62,482 (13.1) <0.0001
Hypertension 390,577 (29.9) 124,983 (36.77) 140,539 (29.46) <0.0001
Dyslipidemia 276,664 (21.18) 76,057 (22.38) 94,100 (19.72) <0.0001
Age, years 53.38 ± 10.16 53.42 ± 9.72 50.89 ± 8.95 <0.0001
Height, cm 158.88 ± 7.89 168.24 ± 6.23 168 ± 6.63 <0.0001
Weight, kg 60.16 ± 9.85 69.19 ± 9.62 67.36 ± 10.4 <0.0001
BMI, kg/m2 23.77 ± 3.06 24.4 ± 2.8 23.81 ± 3.03 <0.0001
Waist Circumference, cm 79.14 ± 8.64 84.69 ± 7.43 83.29 ± 7.86 <0.0001
Systolic BP, mmHg 122.9 ± 15.74 126.19 ± 14.58 124.67 ± 15.05 <0.0001
Diastolic BP, mmHg 76.25 ± 10.3 78.92 ± 9.93 78.29 ± 10.23 <0.0001
Fasting glucose, mg/dL 98.18 ± 23.76 102.87 ± 27.04 102.52 ± 30.45 <0.0001
Total Cholesterol, mg/dL 198.81 ± 36.93 197.91 ± 36.81 198.61 ± 37.38 <0.0001
HDL-C, mg/dL 57.28 ± 30.43 53.42 ± 25.44 52.98 ± 26.26 <0.0001
LDL-C, mg/dL 118.27 ± 38.32 115.1 ± 37.79 112.97 ± 39.36 <0.0001
Triglyceride, mg/dL 106.45 (106.35–106.55) 129.56 (129.32–129.81) 142.5 (142.27–142.73) <0.0001

Data are presented as mean ± standard deviation or n (%). Data are presented as median (interquartile range). p-values were derived from one-way analysis of variance (ANOVA) for continuous variables and the chi-square test for categorical variables. Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

In terms of demographic characteristics, the current smoker group was the youngest, with a mean age of 50.89 ± 8.95 years, compared to 53.38 ± 10.16 years in never smokers and 53.42 ± 9.72 years in former smokers. The proportion of participants aged 40–64 years was highest among current smokers (90.62%). There were substantial differences in sex distribution: the majority of former (96.68%) and current (94.17%) smokers were male, whereas never smokers were predominantly female (72.65%). The proportion of individuals in the lowest income quartile (Q1) was highest in the never smoking group (22.49%) and lowest in the former smoker group (14.7%).

Regarding anthropometric and lifestyle factors, the prevalence of class I obesity (BMI 25.0–29.9) was highest among former smokers (37.85%), who also had the highest mean BMI (24.4 ± 2.8 kg/m2) and waist circumference (84.69 ± 7.43 cm). Non-drinking was most prevalent among never smokers (73.05%), whereas heavy drinking was most common among current smokers (18.52%). Regular physical activity was highest in former smokers (27.33%) and lowest in current smokers (18.07%).

For clinical characteristics, the prevalence of diabetes mellitus (13.7%), hypertension (36.77%), and dyslipidemia (22.38%) was highest in the former smoker group. Mean systolic blood pressure (126.19 ± 14.58 mmHg), diastolic blood pressure (78.92 ± 9.93 mmHg), and fasting glucose levels (102.87 ± 27.04 mg/dL) were also highest in this group. Total cholesterol levels were similar across groups: never (198.81), former (197.91), and current (198.61) smokers. HDL-cholesterol was highest in never smokers (57.28 ± 30.43 mg/dL) and lowest in current smokers (52.98 ± 26.26 mg/dL). LDL-cholesterol was lowest in current smokers (112.97 ± 39.36 mg/dL). Triglyceride levels, which were not normally distributed, had the highest median value in current smokers (142.5 mg/dL, IQR: 142.27–142.73), followed by former (129.56 mg/dL) and never smokers (106.45 mg/dL).

These pronounced differences among groups highlight the importance of multivariable adjustment in subsequent analyses.

Current smokers demonstrated greater cumulative smoking exposure (longer duration and higher pack-years) compared to former smokers, which is consistent with their higher prevalence of dyslipidemia and diabetes at baseline.

3.2. Association Between Smoking and Risk of LSS

Each analysis was based on population sizes ranging from approximately 1.3 million to 470,000 individuals per smoking category. The number of participants and incident cases by group is presented in Table 2. All counts and rates herein reflect the primary LSS definition of ≥3 M48.06 claims on distinct service dates (index date = third claim).

Table 2.

Association between smoking-related exposure and risk of LSS.


N Event Duration IR,
per 1000 PY
HR (95% C.I)
Model 1 Model 2 Model 3 Model 4
Smoking
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
Former 339,915 101,758 2,877,221.61 35.3668 0.761 (0.756, 0.766) 1.064 (1.056, 1.073) 1.049 (1.040, 1.058) 1.047 (1.039, 1.056)
Current 477,104 131,416 4,077,436.53 32.2301 0.694 (0.689, 0.698) 1.054 (1.046, 1.062) 1.054 (1.045, 1.062) 1.052 (1.044, 1.060)
p-value <0.0001 <0.0001 <0.0001 <0.0001
Smoking duration
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
<10 75,749 20,695 660,591.29 31.328 0.674 (0.665, 0.684) 1.008 (0.994, 1.023) 1.005 (0.991, 1.020) 1.005 (0.990, 1.019)
<20 182,604 46,539 1,614,862.4 28.8192 0.620 (0.615, 0.626) 1.013 (1.002, 1.024) 1.003 (0.992, 1.014) 1.001 (0.991, 1.012)
≥20 558,666 165,940 4,679,204.45 35.4633 0.763 (0.759, 0.768) 1.082 (1.074, 1.090) 1.076 (1.068, 1.084) 1.074 (1.066, 1.082)
p-value <0.0001 <0.0001 <0.0001 <0.0001
Smoking amount
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
<10 87,076 25,932 727,072.87 35.6663 0.768 (0.758, 0.777) 0.999 (0.986, 1.012) 1.007 (0.994, 1.020) 1.007 (0.994, 1.020)
<20 301,014 81,915 2,595,251.76 31.5634 0.679 (0.674, 0.684) 1.009 (1.000, 1.018) 1.013 (1.004, 1.022) 1.011 (1.003, 1.020)
≥20 428,929 125,327 3,632,333.51 34.5032 0.743 (0.738, 0.747) 1.118 (1.109, 1.127) 1.097 (1.088, 1.106) 1.095 (1.086, 1.104)
p-value <0.0001 <0.0001 <0.0001 <0.0001
Pack-year
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
<10 194,823 52,573 1,695,866.69 31.0007 0.667 (0.661, 0.673) 0.996 (0.986, 1.006) 0.996 (0.986, 1.006) 0.995 (0.985, 1.005)
<20 231,190 60,742 2,015,666.62 30.1349 0.649 (0.643, 0.654) 1.016 (1.006, 1.026) 1.013 (1.003, 1.023) 1.011 (1.001, 1.021)
<30 194,542 52,777 1,677,908.99 31.454 0.677 (0.671, 0.683) 1.057 (1.046, 1.068) 1.047 (1.037, 1.058) 1.045 (1.034, 1.056)
<40 112,150 35,842 924,688.79 38.7611 0.835 (0.826, 0.844) 1.141 (1.128, 1.155) 1.127 (1.114, 1.141) 1.125 (1.112, 1.139)
≥40 84,314 31,240 640,527.06 48.7723 1.052 (1.040, 1.064) 1.223 (1.208, 1.238) 1.208 (1.193, 1.224) 1.207 (1.191, 1.222)
p-value <0.0001 <0.0001 <0.0001 <0.0001

IR, incidence rate (per 1000 person-years); HR, hazard ratio; CI, confidence interval. Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: Model 2 + income, body mass index (BMI), alcohol consumption, and regular physical activity; Model 4: Model 3 + diabetes mellitus, hypertension, and dyslipidemia. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

During a total follow-up period of 17,482,048.38 person-years, 721,909 new cases of LSS were identified (incident LSS required ≥3 M48.06 claims on distinct dates, with the third claim defining the diagnosis date). Although the crude incidence rate of LSS appeared to be the highest among never smokers, this likely reflects confounding due to age and sex composition, as this group was significantly older and more female-dominant. Therefore, these unadjusted rates should be interpreted cautiously and not as evidence of a protective effect of smoking (Figure 2). This counterintuitive pattern is likely attributable to demographic differences, given that the never smoker group was older on average and predominantly female. Across smoking exposure metrics, crude absolute incidence rates (per 1000 person-years) increased with heavier lifetime smoking; for pack-years, IRs ranged from 31.0 in <10 pack-years to 48.8 in ≥40 pack-years (Table 2). Consistently, in the unadjusted analysis (Model 1), current smoking appeared to be associated with a 30.6% lower risk of LSS (HR 0.694; 95% CI, 0.689–0.698) (Figure 3).

Figure 2.

Figure 2

Cumulative incidence of LSS by smoking-related variables over 10 years. (a) Smoking status: Highest in never smokers, followed by former and current smokers. (b) Smoking duration: ≥20 years showed higher incidence than shorter durations. (c) Smoking amount: ≥20 cigarettes/day had the highest incidence among smokers. (d) Pack-year: Incidence increased with higher pack-year categories, peaking at ≥40 pack-years. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A2 of Appendix A, which can be cross-referenced for at-risk denominators.

Figure 3.

Figure 3

Hazard ratios (HRs) for LSS by smoking-related variables (never smokers as reference, HR = 1.0). (a) Smoking status: Fully adjusted HRs were higher in both former and current smokers. (b) Smoking duration: Risk increased in the ≥20 years group. (c) Smoking amount: ≥20 cigarettes/day had the highest HR among amount categories. (d) Pack-year: HRs rose progressively with greater pack-year exposure, highest in ≥40 pack-years.

After adjustment for age and sex (Model 2), both former (HR 1.064) and current smokers (HR 1.054) showed a significantly increased risk compared to never smokers. These associations persisted in Model 3, which were further adjusted for income level, BMI, alcohol consumption, and physical activity.

In the fully adjusted model (Model 4), which accounted for age, sex, lifestyle factors, and comorbidities, a statistically significant positive association between smoking and incident LSS was observed. Compared with never smokers, the risk was elevated by 4.7% in former smokers (HR 1.047; 95% CI, 1.039–1.056) and 5.2% in current smokers (HR 1.052; 95% CI, 1.044–1.060). Notably, the fully adjusted estimates were close to the age–sex adjusted estimates (Model 2), indicating the limited impact of additional lifestyle and metabolic covariates on the effect size.

A clear dose–response relationship was observed, in which greater cumulative smoking exposure was associated with increased risk. For smoking duration, individuals who had smoked for ≥20 years exhibited a significantly increased risk (HR 1.074; 95% CI, 1.066–1.082), whereas those who smoked for <20 years did not show a significant difference. Daily cigarette consumption showed similar trends: smoking 10–19 cigarettes per day was associated with a modest increase (HR 1.011; 95% CI, 1.003–1.020), while ≥20 cigarettes per day was associated with a notably higher risk (HR 1.095; 95% CI, 1.086–1.104).

The most pronounced dose–response trend was observed for cumulative smoking exposure, measured as pack-years. Risk increased stepwise with higher pack-year categories: HR 1.011 for <20 pack-years, HR 1.045 for 20–29, HR 1.125 for 30–39, and HR 1.207 (95% CI, 1.191–1.222) for ≥40 pack-years. The trend was statistically significant (p for trend <0.0001).

3.2.1. Heterogeneity of Smoking Risk by Age

The association between smoking and LSS risk varied substantially by age group. In the dichotomized analysis (<65 vs. ≥65 years), both former and current smoking were associated with modest risk increases in the younger group (HR 1.016 and 1.027, respectively), whereas in participants aged ≥ 65 years, the increases were more pronounced (HR 1.146 and 1.174, respectively). Similar patterns were observed for smoking duration, daily cigarette consumption, and pack-years, with stronger associations in older adults. These patterns are visualized in Figure 4 and Figure 5, which show cumulative incidence and hazard ratio plots, respectively, for participants aged 40–64 and those aged ≥ 65 years. Sex- and age-stratified analyses using 10-year age bands (40–49, 50–59, 60–69, and ≥70 years) yielded consistent findings and are presented in Appendix A. Crude absolute incidence rates (IRs per 1000 person-years) were substantially higher in older adults. By smoking status, IRs were 41.9/31.7/29.9 (never/former/current) in ages 40–64 versus 77.6/62.6/63.0 in ages ≥65 (Table A1 of Appendix A). Across exposure metrics, the ≥65 group consistently showed IRs around 60–67, peaking at 66.6 in the ≥40 pack-years category, compared with 28.8–42.8 in ages 40–64 (Table A1 of Appendix A). Stratification by 10-year age bands showed a monotonic rise in non-smoker IRs from 30.6 (40–49 years) to 49.7 (50–59), 72.8 (60–69), and 76.8 (≥70), with parallel increases across exposure categories (Table A2 of Appendix A).

Figure 4.

Figure 4

Cumulative incidence of LSS by smoking-related variables, stratified by age groups (40–64 years and ≥65 years). (a) Smoking status; (b) Smoking duration; (c) Smoking amount (cigarettes/day); (d) Pack-year. Cumulative incidence curves were estimated over a 10-year follow-up period for two age groups. Different line styles within each panel represent categories of the smoking variable. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A1 of Appendix A, which can be cross-referenced for at-risk denominators.

Figure 5.

Figure 5

Hazard ratios (HRs) with 95% confidence intervals for LSS by smoking-related variables, stratified by age groups (40–64 years and ≥65 years). (a) Smoking status; (b) Smoking duration; (c) Smoking amount (cigarettes/day); (d) Pack-year. HRs were derived from the fully adjusted Cox proportional hazards model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. The horizontal dotted line represents HR = 1.0.

Detailed estimates for the dichotomized age analysis are provided in Table A1 of Appendix A, while the results for 10-year age bands are shown in Table A2 of Appendix A and Figure A1 and Figure A2 of Appendix A.

3.2.2. Heterogeneity of Smoking Risk by Sex

Marked sex differences were observed in the association between smoking and LSS, with women appearing more susceptible to the harmful effects of smoking than men. Among current smokers, women had a substantially greater relative risk increase compared with men. Former smoking was associated with an elevated risk in men but showed no significant association in women. Across all smoking duration, amount, and cumulative exposure categories, women generally exhibited higher risk than men, even at lower exposure levels. These patterns were consistent in both cumulative incidence curves and fully adjusted hazard ratio models (Figure 6 and Figure 7; detailed results in Table A3). Sex-specific crude IRs diverged markedly. In men, IRs were 34.7 (never), 34.9 (former), and 30.9 (current); in women, the corresponding IRs were 51.1, 48.4, and 56.8 (Table A3 of Appendix A). At comparable exposures, women had higher absolute rates—for example, ≥20 pack-years: 48.6 in men vs. 81.3 in women; ≥20 years: 34.9 vs. 66.8; ≥20 cigarettes/day: 34.1 vs. 64.0 (Table A3 of Appendix A).

Figure 6.

Figure 6

Cumulative incidence of LSS by smoking-related variables, stratified by sex. Male participants are shown in blue and female participants in red, with different line styles representing categories within each smoking variable. Curves were estimated over a 10-year follow-up period. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A3 of Appendix A, which can be cross-referenced for at-risk denominators.

Figure 7.

Figure 7

Fully adjusted hazard ratios (Model 4) with 95% confidence intervals for LSS by smoking-related variables, stratified by sex. Adjustments included age, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. The horizontal dashed line indicates HR = 1.0.

3.3. Combined Effect of Smoking Cessation and Cumulative Smoking Burden

To investigate the long-term effect of cumulative smoking exposure and the impact of smoking cessation, we conducted a composite analysis combining smoking status (former vs. current smokers) with detailed exposure indicators, including smoking duration, daily cigarette consumption, and cumulative pack-years. These composite results are presented in Table 3, which summarizes the adjusted hazard ratios (Model 4) across smoking status and exposure level combinations. Crude absolute incidence rates (per 1000 person-years) for each combined category are also reported in Table 3; for illustration, IRs were 46.4 in never smokers, 42.1 in former smokers with ≥20 pack-years, and 34.6 in current smokers with ≥20 pack-years.

Table 3.

Hazard ratios (HRs) and 95% confidence intervals (CIs) for LSS by combined smoking status and cumulative smoking exposure: duration, amount, and pack-year.

N Event Duration IR,
per 1000
HR (95% C.I)
Model 1 Model 2 Model 3 Model 4
Smoking status and Duration
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
Ex and <10 50,731 13,488 445,496.19 30.2764 0.652 (0.641, 0.663) 0.981 (0.964, 0.998) 0.979 (0.962, 0.996) 0.978 (0.961, 0.995)
Ex and <20 110,117 29,059 969,121.1 29.9849 0.645 (0.638, 0.653) 1.024 (1.011, 1.037) 1.008 (0.995, 1.021) 1.007 (0.994, 1.020)
Ex and ≥20 179,067 59,211 1,462,604.32 40.4833 0.872 (0.865, 0.879) 1.112 (1.101, 1.123) 1.093 (1.082, 1.104) 1.091 (1.080, 1.102)
Current and <10 25,018 7207 215,095.1 33.5061 0.721 (0.704, 0.738) 1.063 (1.038, 1.088) 1.058 (1.033, 1.083) 1.057 (1.032, 1.082)
Current and <20 72,487 17,480 645,741.3 27.0697 0.583 (0.574, 0.592) 0.994 (0.979, 1.010) 0.992 (0.977, 1.008) 0.991 (0.975, 1.006)
Current and ≥20 379,599 106,729 3,216,600.13 33.1807 0.714 (0.709, 0.719) 1.066 (1.057, 1.075) 1.066 (1.057, 1.075) 1.065 (1.056, 1.074)
Smoking status and amount
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
Ex and <10 40,665 12,027 345,340.08 34.8265 0.750 (0.736, 0.763) 0.993 (0.975, 1.011) 0.998 (0.979, 1.016) 0.997 (0.979, 1.016)
Ex and <20 128,117 35,973 1,105,256.62 32.5472 0.700 (0.693, 0.708) 1.011 (0.999, 1.023) 1.007 (0.995, 1.019) 1.006 (0.994, 1.017)
Ex and ≥20 171,133 53,758 1,426,624.91 37.6819 0.811 (0.804, 0.819) 1.132 (1.120, 1.143) 1.100 (1.089, 1.111) 1.097 (1.086, 1.109)
Current and <10 46,411 13,905 381,732.79 36.426 0.784 (0.771, 0.798) 1.004 (0.987, 1.021) 1.015 (0.998, 1.033) 1.015 (0.997, 1.032)
Current and <20 172,897 45,942 1,489,995.14 30.8337 0.664 (0.657, 0.670) 1.007 (0.996, 1.018) 1.017 (1.006, 1.028) 1.016 (1.005, 1.027)
Current and ≥20 257,796 71,569 2,205,708.61 32.4472 0.698 (0.693, 0.704) 1.107 (1.097, 1.118) 1.095 (1.084, 1.105) 1.092 (1.082, 1.103)
Smoking status and Pack-year
None 1,306,249 488,735 10,527,390.24 46.4251 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
Ex and <10 112,688 30,325 985,606.07 30.7679 0.662 (0.655, 0.670) 0.988 (0.976, 1.000) 0.987 (0.974, 0.999) 0.986 (0.973, 0.998)
Ex and <20 99,797 28,095 861,820.86 32.5996 0.702 (0.693, 0.710) 1.043 (1.029, 1.056) 1.027 (1.014, 1.041) 1.025 (1.012, 1.039)
Ex and ≥20 127,430 43,338 1,029,794.68 42.0841 0.907 (0.898, 0.916) 1.155 (1.142, 1.168) 1.126 (1.113, 1.139) 1.123 (1.111, 1.136)
Current and <10 82,135 22,248 710,260.62 31.3237 0.674 (0.665, 0.683) 1.008 (0.995, 1.022) 1.011 (0.997, 1.026) 1.010 (0.996, 1.025)
Current and <20 131,393 32,647 1,153,845.75 28.2941 0.609 (0.603, 0.616) 0.995 (0.983, 1.007) 1.002 (0.990, 1.014) 1.000 (0.988, 1.013)
Current and ≥20 263,576 76,521 2,213,330.16 34.5728 0.744 (0.738, 0.750) 1.103 (1.093, 1.113) 1.098 (1.088, 1.109) 1.097 (1.087, 1.107)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted model (Model 4). Definitions of IR, HR, CI, Model 4, and reference group are provided in the footnote of Table 2. Smoking duration categories: <10, <20, ≥20 years; smoking amount: <10, <20, ≥20 cigarettes/day; pack-year: <10, <20, ≥20 pack-years. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

A notable finding was that among individuals with ≥20 pack-years of smoking history, former smokers (HR 1.126, 95% CI 1.113–1.139) exhibited a higher risk of LSS than current smokers (HR 1.097, 95% CI 1.087–1.107). This pattern was consistent in those with ≥20 years of smoking (former: HR 1.091 vs. current: HR 1.065) and in those who had smoked ≥20 cigarettes per day (former: HR 1.097 vs. current: HR 1.092). These findings suggest possible irreversible damage from prolonged smoking or the presence of a “sick quitter effect,” wherein individuals with deteriorating health may be more likely to quit.

Among former smokers, a dose–response relationship by past smoking burden was evident. There was no increased risk for <10 pack-years (HR 0.986), but the risk increased to 2.5% in the 10–19 pack-year group (HR 1.025, 95% CI 1.012–1.039) and 12.6% in the ≥20 pack-year group (HR 1.126, 95% CI 1.113–1.139).

Similar trends were observed for smoking duration and daily amount. Former smokers with ≥20 cigarettes per day had a higher risk (HR 1.097; 95% CI 1.086–1.109), as did those with ≥20 years of smoking (HR 1.091; 95% CI 1.080–1.102), compared to current smokers with equivalent exposure. These results indicate that cumulative exposure history may outweigh current smoking status in determining stenosis risk.

Among current smokers, increased risk was primarily limited to those with heavy cumulative exposure. No significant increase was observed for <20 pack-years, whereas those with ≥20 pack-years showed a 9.7% increased risk (HR 1.097, 95% CI 1.087–1.107).

In summary, the risk of LSS appeared to be more strongly driven by cumulative smoking burden than by current smoking status. Long-term, heavy smoking left substantial residual risk even after cessation.

Cumulative incidence curves and multivariable-adjusted hazard ratios by smoking status and cumulative exposure are illustrated in Figure 8 and Figure 9, respectively.

Figure 8.

Figure 8

Cumulative incidence of LSS by combined smoking status and exposure level over 10 years. (a) Smoking duration; (b) Smoking amount (cigarettes/day); (c) Pack-year. Former smokers are shown in blue and current smokers in red, with line styles indicating exposure level categories for each variable. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table 3, which can be cross-referenced for at-risk denominators.

Figure 9.

Figure 9

Hazard ratios (HRs) with 95% confidence intervals for LSS by combined smoking status and exposure level (Models 1–4). (a) Smoking duration; (b) Smoking amount (cigarettes/day); (c) Pack-year. HRs were derived from Cox models, with Model 4 fully adjusted for demographic, lifestyle, and comorbidity factors. The horizontal dashed line represents HR = 1.0, and error bars indicate 95% confidence intervals.

3.3.1. Age-Stratified Effects of Combined Smoking Burden and Cessation

Age-stratified analysis showed clear heterogeneity in the effects of smoking cessation and cumulative exposure. Detailed results are provided in Table A4 of Appendix B, with corresponding cumulative incidence curves and hazard ratios in Figure 10 and Figure 11. In the combined status–exposure categories, absolute rates were consistently higher in ≥65 years. For current smokers with ≥20 pack-years, the IR was 31.8 in ages 40–64 vs. 63.0 in ≥65; for ≥20 cigarettes/day, 30.6 vs. 64.4; and for ≥20 years of smoking, 30.4 vs. 62.9. Among former smokers with ≥20 pack-years, IRs were 37.2 (40–64) vs. 64.5 (≥65). Baseline non-smoker IRs mirrored this age gap (41.9 vs. 77.6) (Table A4 of Appendix B).

Figure 10.

Figure 10

Cumulative incidence of LSS by combined smoking status and cumulative exposure (duration, amount, pack-years), stratified by age group (40–64 years and ≥65 years). In both age groups, higher cumulative exposure was associated with increased incidence, with the steepest curves in older current smokers with heavy exposure. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A4 of Appendix B, which can be cross-referenced for at-risk denominators.

Figure 11.

Figure 11

Fully adjusted hazard ratios (Model 4) for LSS by combined smoking status and cumulative exposure, stratified by age group. Risk increased with greater cumulative exposure in both former and current smokers, with consistently higher HRs in the ≥65 years group. Smoking cessation reduced risk but did not fully offset the effects of heavy lifetime exposure.

In adults aged 40–64 years, elevated risk was observed mainly in those with high cumulative exposure (≥20 years, ≥20 cigarettes/day, or ≥20 pack-years), regardless of smoking status. Lower exposure levels showed minimal or no significant increase in risk.

In adults aged ≥65 years, the risk was consistently higher across almost all exposure categories, with the greatest risk in current smokers with heavy exposure (e.g., ≥20 cigarettes/day: HR 1.267; ≥20 pack-years: HR 1.220). Even former smokers with low exposure (<10 pack-years) showed increased risk (HR 1.093).

Overall, cumulative smoking exposure over time had a stronger influence on LSS risk than current smoking status alone. Notably, among adults aged ≥65 years, smoking cessation was associated with a meaningful reduction in risk, supporting the benefits of cessation even in late life.

Additional detailed stratified analyses using 10-year age bands (40–49, 50–59, 60–69, and ≥70 years) are provided in Table A5 and Figure A3 and Figure A4 of Appendix B. These analyses further highlight nuanced age-related variations, including elevated risk among former smokers in their 60s and the highest risk among current smokers with heavy exposure in the ≥70 age group.

3.3.2. Sex-Stratified Effects of Combined Smoking Burden and Cessation

Sex-specific patterns were evident in the association between combined smoking burden and the risk of LSS. In men, prolonged smoking history was associated with a sustained elevation in risk, even after cessation. Former smokers with ≥20 years of smoking exhibited a hazard ratio (HR) of 1.080 (95% confidence interval [CI] 1.069–1.091), and current smokers with the same duration had an HR of 1.049 (95% CI 1.040–1.059). Interestingly, current smokers with 10–19 years of smoking demonstrated a reduced risk (HR 0.931, 95% CI 0.914–0.948). For heavy exposure, defined as ≥20 cigarettes/day or ≥20 pack-years, both former smokers (HR 1.084 and HR 1.109, respectively) and current smokers (HR 1.073 and HR 1.079, respectively) had significantly elevated risks. Across these high-exposure categories, former smokers consistently showed slightly higher risk than current smokers, suggesting the presence of irreversible damage and a possible “sick quitter effect.”

In women, current smoking emerged as a strong and independent risk factor across all categories of smoking duration, daily amount, and pack-years. Hazard ratios for current smokers ranged from 1.129 to 1.191 by duration, with the highest risks observed in those smoking ≥20 cigarettes/day (HR 1.266, 95% CI 1.217–1.316) and those with ≥20 pack-years (HR 1.195, 95% CI 1.142–1.251). In contrast, former smokers generally exhibited no significant excess risk, except for those with ≥20 cigarettes/day (HR 1.091, 95% CI 1.013–1.174) or 10–19 pack-years (HR 1.097, 95% CI 1.015–1.186), indicating a more immediate and pronounced risk reduction following cessation compared to men.

Overall, men demonstrated persistent risk following long-term heavy smoking despite cessation, whereas in women, the adverse effects were driven primarily by current smoking, with cessation associated with rapid and substantial attenuation of risk.

These sex-specific trends were consistently observed in both cumulative incidence curves and adjusted hazard ratio plots (Figure 12 and Figure 13), with detailed numerical estimates provided in Table A6 of Appendix B. Sex-specific incidence rates revealed a consistent gap across all smoking exposure categories. Among current smokers with ≥20 pack-years, the rate was 72.8 per 1000 person-years in women versus 34.1 in men; for ≥20 cigarettes/day, 65.0 vs. 31.9; and for ≥20 years, 66.8 vs. 32.4. Even among former smokers with ≥20 pack-years, the gap persisted (71.7 in women vs. 41.9 in men). Non-smokers also showed a notable difference: 51.1 in women vs. 34.7 in men (Table A6 of Appendix B).

Figure 12.

Figure 12

Cumulative incidence of LSS by combined smoking status and exposure level, stratified by sex: (a) smoking duration, (b) smoking amount (cigarettes/day), and (c) pack-years. Curves are based on a 10-year follow-up, with former smokers shown in blue and current smokers in red. Different line styles indicate exposure level categories within each smoking variable. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A6 of Appendix B, which can be cross-referenced for at-risk denominators.

Figure 13.

Figure 13

Hazard ratios (HRs) with 95% confidence intervals for LSS by combined smoking status and exposure level, stratified by sex (Model 4). Analyses were adjusted for age, body mass index, income, alcohol consumption, regular exercise, diabetes, hypertension, and dyslipidemia. The horizontal dashed line represents HR = 1.0; error bars indicate 95% confidence intervals.

3.4. Association of Smoking with LSS Risk by Subgroups and Interaction Analysis

Lastly, subgroup and interaction analyses were conducted to examine whether the effect of smoking differed significantly according to major demographic and clinical characteristics. The results are presented in Table A7.

Several demographic and clinical factors significantly modified the association between smoking and LSS risk. The strongest effect modification was observed for age and sex. Among participants aged ≥65 years, current and former smoking increased the risk by more than 14%, whereas in those aged 40–64 years, the increase was minimal. Women showed a markedly higher risk with current smoking (+16.1%) compared to men (+3.2%), while former smoking increased risk only in men. The interaction between sex and smoking status was statistically significant (p for interaction <0.0001), as shown in Appendix C.1, indicating that the association of smoking with LSS risk was significantly stronger in women than in men. Other significant modifiers included income, obesity status (by BMI and waist circumference), hypertension, heavy drinking, and regular exercise. In contrast, the associations were consistent across diabetes and dyslipidemia subgroups. Detailed subgroup-specific hazard ratios and interaction p-values are provided in Figure 14.

Figure 14.

Figure 14

Multivariable subgroup analysis of the association between smoking and risk of LSS (Model 4). (a) Hazard ratios (HRs) with 95% confidence intervals (CIs) for former and current smokers compared with never smokers, presented by subgroup in the original variable order (Yes/No). This format allows direct comparison between categories within each variable. (b) Same data as in (a), but subgroups are sorted in descending order of HR for current smokers, highlighting groups with the greatest relative risk (e.g., age ≥65 years, female sex). HRs were derived from the fully adjusted Cox proportional hazards model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. Horizontal bars represent 95% CIs, with red indicating current smokers and blue indicating former smokers.

These results are visually summarized in Figure 14, which displays the hazard ratios and 95% confidence intervals for each subgroup in both the original variable order and in descending order of hazard ratio for current smokers, highlighting the groups with the greatest relative risk.

4. Discussion

For illustration, if the crude incidence rate in never smokers is approximately 46 per 1000 person-years, a 5% relative increase would correspond to 2–3 additional cases per 1000 person-years. Although modest at the individual level, this becomes a considerable burden at the population level given the high prevalence of smoking.

A clear dose–response pattern reinforces that cumulative lifetime smoking—more than current status alone—is the dominant driver of LSS risk, with the highest risk observed in heavy long-term smokers. Accordingly, counseling should quantify lifetime exposure (e.g., pack-years) and prioritize cessation for individuals with a substantial cumulative burden.

Despite extensive multivariable adjustment, residual confounding cannot be excluded, particularly from unmeasured factors such as prior spine trauma, occupational mechanical load (e.g., heavy lifting, vibration), analgesic use, menopausal/hormonal status, secondhand smoke exposure, and genetic predisposition. As an interpretive aid, the E-value for the main HR ≈ 1.05 is ~1.29, implying that an unmeasured confounder associated with both smoking and LSS by a risk ratio of ~1.3 each could, in principle, explain away the association.

The pathophysiology of lumbar spinal stenosis primarily involves the progressive narrowing of the spinal canal, resulting in the compression of neural elements [12]. This narrowing is predominantly driven by degenerative changes, including intervertebral disk degeneration, hypertrophy of the ligamentum flavum, and facet joint arthropathy, which collectively reduce canal diameter. Additional mechanisms, such as reduced microvascular perfusion from atherosclerotic changes, direct mechanical compression, and chronic inflammation, further exacerbate structural deterioration [13]. The observed higher prevalence of dyslipidemia and diabetes among current smokers likely reflects their long-term and heavy smoking history. These metabolic abnormalities promote atherosclerotic microvascular injury and reduced perfusion, providing a biologically plausible mechanism through which heavy or long-term smoking accelerates spinal degeneration and increases the risk of LSS [14,15].

These findings are also consistent with prior international cohort studies, reinforcing the biological plausibility of a smoking–LSS relationship across different populations. Rather than reflecting cultural or healthcare system differences, this consistency suggests a shared underlying pathophysiologic mechanism by which cumulative tobacco exposure accelerates spinal degeneration [8,9,12,16,17].

Tobacco smoking is a major preventable health hazard and is conclusively associated with multiple chronic disorders, including cancer, coronary artery disease, chronic obstructive pulmonary disease, and peripheral vascular disease [18]. In orthopedic and other surgical populations, smoking is well recognized as a risk factor for perioperative complications, such as wound infections, delayed healing, respiratory infections, and myocardial infarction [19]. In Korea, smoking accounted for more than 48,000 deaths in 2019, representing 22.7% of all fatalities that year, underscoring the substantial burden on the healthcare system [20].

After full multivariable adjustment, cigarette smoking remained an independent risk factor for LSS, indicating that the observed association is unlikely to be explained solely by demographic or lifestyle differences. This pattern underscores that the duration and intensity of smoking—rather than smoking status alone—drive spinal degeneration. In particular, long-term and heavy smoking appears to induce vascular and structural changes that may persist even after cessation, which helps explain the residual risk observed among former smokers.

The susceptibility to smoking-related risk was not uniform across the population. Older adults and women demonstrated a disproportionately higher vulnerability, suggesting an interaction between tobacco-related microvascular damage and age-related spinal degeneration, as well as potential hormonal or metabolic factors that may amplify the adverse effects of smoking. These findings highlight that the biological impact of smoking on the spine is modified by both age and sex, reinforcing the need for tailored preventive counseling in high-risk subgroups.

These findings extend prior international evidence by showing that the association between smoking and LSS persists after rigorous adjustment for lifestyle and metabolic factors. By leveraging multidimensional smoking metrics in a large, nationally representative cohort, our study demonstrates that long-term cumulative exposure—not smoking status alone—underlies the biological pathway linking smoking to spinal degeneration.

From a clinical standpoint, these findings underscore the importance of incorporating smoking history into LSS risk assessment and patient counseling, particularly for older adults and women, who constitute key high-risk subgroups. In orthopedic practice, preoperative screening for smoking status in patients scheduled for lumbar decompression or fusion surgery could help identify those at higher risk for postoperative complications and long-term functional decline. Furthermore, the observed dose–response relationship supports the potential benefit of smoking cessation programs not only for cardiovascular and pulmonary health but also for the prevention of degenerative spinal disorders.

Several limitations of this study warrant consideration. First, a key limitation is that smoking status and exposure were self-reported and assessed only at baseline (2009). With a median follow-up of over 10 years, we could not account for changes in smoking behavior, such as cessation, relapse, or changes in intensity, which may have led to misclassification bias. However, such nondifferential misclassification would likely have attenuated the true associations, suggesting that the reported risks may be underestimates. We also acknowledge that a “sick quitter effect” may exist, particularly among former smokers who show a higher risk than their current smoking counterparts. Second, although we implemented a one-year washout period to reduce reverse causation, residual bias cannot be completely excluded. Third, the Korean National Health Insurance System (NHIS) database, which is based on claims records, lacks detailed information on the severity of the disease, specific imaging findings (e.g., degree of canal narrowing, spinal alignment, or prior trauma history), or surgical intervention. Consequently, we could not differentiate between patients with mild versus severe stenosis or those requiring surgical treatment. However, our diagnostic criteria, which require a physician-assigned diagnosis and three or more claims, suggest that our outcome measure represents a clinically meaningful event rather than a mere radiographic finding. In addition, we acknowledge the potential for multicollinearity among smoking variables (duration, amount, pack-years); to minimize bias, these variables were not entered simultaneously into the same model but analyzed separately. Finally, as our cohort consisted exclusively of Korean adults, the generalizability of these findings beyond Korea may be limited. Differences in healthcare systems, smoking patterns, and demographic structures across countries should be considered when extrapolating these results. The NHIS data do not include menopausal status/timing, use of hormone therapy, or osteoporosis measurements; thus, these sex-specific pathways could not be quantified and causal interpretation warrants caution. Beyond acknowledging the absence of several potential confounders, the likely direction of residual bias is as follows. First, cigarette smoking is consistently associated with lower bone mineral density (BMD) and greater bone loss and fracture risk in a dose-dependent manner; lack of BMD adjustment may therefore have biased the smoking–LSS association upward (positive residual confounding) [21]. Second, heavy occupational mechanical loading (e.g., frequent heavy lifting, vibration) is linked to higher LSS risk, and such jobs tend to be more common among smokers; failure to measure occupational load likely overestimates the association [22]. Third, menopausal status and estrogen exposure influence lumbar disk degeneration, particularly within the first 15 years after menopause; unmeasured menopausal factors could amplify the association among women (positive confounding) or act as effect modifiers of the smoking–LSS relationship [23]. Finally, secondhand smoke has been associated with impaired bone health and higher fracture risk; if correlated with active smoking in our cohort, unmeasured environmental exposure could also bias estimates upward [24]. Taken together, some unmeasured factors likely bias estimates away from the null; however, the direction may vary by sex-specific pathways, and our sex-stratified analyses may mitigate but do not eliminate such bias.

In addition, because survival analyses were based on aggregated summary-level data, numbers at risk could not be shown beneath the cumulative incidence curves. Instead, group-specific participant counts and events were provided in the Appendix A Table A3 to support interpretability.

Despite these limitations, the strengths of our study include its large sample size, nationwide coverage, extended follow-up, comprehensive adjustment for demographic and clinical variables, and the ability to examine detailed exposure–response patterns using multiple smoking indicators.

Given the observed association between long-term smoking and the increased risk of lumbar spinal stenosis, our findings underscore the importance of smoking cessation or reduction as part of preventive strategies for degenerative spinal disorders. Counseling patients—particularly older adults—on smoking cessation may contribute not only to general cardiovascular and metabolic health, but also to reducing the burden of spinal stenosis in the aging population. This reinforces that smoking cessation should be emphasized not only for cardiovascular and metabolic outcomes, but also as part of musculoskeletal health preservation strategies.

In addition to influencing disease onset, smoking also has important implications for postoperative recovery and structural healing within the spine. Cigarette smoking is well known to impair bone healing and delay spinal fusion, meaning that it can hinder not only prevention efforts but also postsurgical outcomes. Accordingly, counseling strategies should emphasize both the prevention of disease progression and optimization of postoperative recovery. Educating patients about the detrimental effects of smoking on bone regeneration and supporting cessation efforts may improve fusion success and overall postoperative outcomes.

In conclusion, our study provides robust epidemiologic evidence that cigarette smoking was independently associated with LSS, reinforcing its role as a modifiable risk factor. The magnitude of risk is particularly high among older adults, women, and long-term heavy smokers. These findings highlight the potential role of smoking cessation strategies in mitigating spinal degeneration and improving quality of life in at-risk populations. Future prospective studies incorporating imaging biomarkers, longitudinal exposure assessment, and biochemical measures of disk degeneration will be essential to more precisely delineate the biological pathways through which smoking contributes to lumbar spinal degeneration.

Appendix A

Appendix A.1. Association Between Smoking and LSS by Dichotomized Age Groups (<65 vs. ≥65 Years)

This appendix section provides the detailed numerical estimates for the primary age-stratified analysis described in Section 3.2.1. In the dichotomized analysis, both former and current smoking were associated with modest risk increases in younger adults (<65 years; HR 1.016 and 1.027, respectively), whereas in participants aged ≥ 65 years, the increases were more pronounced (HR 1.146 and 1.174, respectively). Results for smoking duration, daily amount, and pack-years showed a similar pattern, with stronger associations in older adults. The corresponding figures depicting cumulative incidence and adjusted hazard ratios are presented in the main text (Figure 4 and Figure 5).

Table A1.

Association between smoking-related variables and risk of LSS by dichotomized age groups (<65 vs. ≥65 years).

Age 40–64 Years Age ≥65 Years
N Event Duration IR, per 1000 PY Model 4 N Event Duration IR, per 1000 PY Model 4
Smoking
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
Former 289,693 80,465 2,537,191.47 31.7142 1.016 (1.007, 1.025) 50,222 21,293 340,030.13 62.6209 1.146 (1.129, 1.164)
Current 432,328 113,120 3,787,142.02 29.8695 1.027 (1.019, 1.036) 44,776 18,296 290,294.51 63.0256 1.174 (1.155, 1.193)
Smoking duration
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
<10 70,412 18,446 623,498.34 29.5847 0.991 (0.976, 1.006) 5337 2249 37,092.96 60.6315 1.088 (1.043, 1.135)
<20 172,790 42,370 1,546,564.87 27.3962 0.988 (0.977, 0.999) 9814 4169 68,297.53 61.0417 1.115 (1.080, 1.150)
≥20 478,819 132,769 4,154,270.29 31.9596 1.043 (1.034, 1.051) 79,847 33,171 524,934.15 63.1908 1.172 (1.157, 1.188)
Smoking amount
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
<10 71,438 19,640 624,696.7 31.4393 0.995 (0.980, 1.010) 15,638 6292 102,376.17 61.4596 1.057 (1.030, 1.084)
<20 266,882 67,873 2,365,595.98 28.6917 0.983 (0.974, 0.993) 34,132 14,042 229,655.78 61.1437 1.134 (1.114, 1.155)
≥20 383,701 106,072 3,334,040.82 31.8148 1.063 (1.054, 1.072) 45,228 19,255 298,292.7 64.5507 1.224 (1.204, 1.244)
Pack-year
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
<10 178,284 45,617 1,583,458.76 28.8085 0.980 (0.969, 0.990) 16,539 6956 112,407.93 61.8818 1.085 (1.059, 1.112)
<20 211,197 52,527 1,880,898.38 27.9265 0.992 (0.982, 1.002) 19,993 8215 134,768.24 60.9565 1.117 (1.091, 1.142)
<30 175,174 44,869 1,548,869.83 28.9689 1.025 (1.014, 1.037) 19,368 7908 129,039.16 61.2837 1.150 (1.123, 1.177)
<40 98,322 30,092 832,115.32 36.1633 1.093 (1.079, 1.107) 13,828 5750 92,573.46 62.1128 1.176 (1.144, 1.208)
≥40 59,044 20,480 478,991.21 42.7565 1.170 (1.152, 1.188) 25,270 10,760 161,535.85 66.6106 1.265 (1.239, 1.291)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted model (Model 4). IR and variable definitions are as described in the footnote of Table 2. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Appendix A.2. Association Between Smoking and LSS by 10-Year Age Bands (40–49, 50–59, 60–69, and ≥70 Years)

Stratification by 10-year age bands revealed progressive increases in smoking-related risk with advancing age. In adults aged 40–49 years, only small but statistically significant elevations were observed for both former (HR 1.026; 95% CI 1.012–1.040) and current smoking (HR 1.029; 95% CI 1.017–1.040). Among those aged 60–69 and ≥70 years, smoking-related risk became more pronounced, with hazard ratios exceeding 1.20 for heavy or prolonged exposure. Detailed estimates are tabulated below, with cumulative incidence curves and adjusted hazard ratios summarized graphically

Table A2.

Association between smoking-related variables and risk of LSS by 10-year age groups.

Age
Group
Category N Events Duration
(PY)
IR
(per 1000 PY)
Model 4 HR
(95% CI)
40–49 years Smoking
None 544,195 148,119 4,834,353.75 30.64 1 (Ref.)
Former 137,294 29,398 1,261,274.29 23.31 1.026 (1.012–1.040)
Current 246,597 51,943 2,254,426.63 23.04 1.029 (1.017–1.040)
Smoking Duration
<10 43,090 9430 393,815.87 23.95 1.013 (0.992–1.035)
<20 115,116 23,654 1,059,616.41 22.32 1.007 (0.992–1.022)
≥20 225,685 48,257 2,062,268.65 23.4 1.045 (1.033–1.058)
Smoking Amount
<10 38,649 8536 352,502.35 24.22 1.011 (0.989–1.034)
<20 147,657 30,050 1,361,334.10 22.07 0.998 (0.985–1.012)
≥20 197,585 42,755 1,801,864.46 23.73 1.061 (1.049–1.074)
Pack-year
<10 108,482 22,804 996,145.73 22.89 0.999 (0.984–1.013)
<20 126,740 25,766 1,168,249.29 22.06 1.012 (0.997–1.026)
<30 105,835 22,383 968,373.34 23.11 1.046 (1.031–1.062)
<40 29,360 6968 263,178.05 26.48 1.137 (1.109–1.166)
≥40 13,474 3420 119,754.50 28.56 1.198 (1.158–1.240)
5 0– 5 9 years Smoking
None 411,790 164,725 3,317,386.08 49.66 1 (Ref.)
Former 112,843 34,982 967,675.15 36.15 1.005 (0.993–1.018)
Current 146,289 45,375 1,233,935.28 36.77 1.032 (1.020–1.044)
Smoking Duration
<10 22,069 6894 188,610.06 36.55 0.980 (0.956–1.004)
<20 46,915 14,410 402,247.15 35.82 0.987 (0.970–1.005)
≥20 190,148 59,053 1,610,753.22 36.66 1.036 (1.025–1.048)
Smoking Amount
<10 24,127 7588 205,330.79 36.96 0.976 (0.954–0.999)
<20 92,067 27,270 791,947.52 34.43 0.974 (0.961–0.988)
≥20 142,938 45,499 1,204,332.13 37.78 1.065 (1.052–1.077)
Pack-year
<10 55,429 17,074 474,632.40 35.97 0.975 (0.959–0.991)
<20 67,291 19,986 578,502.12 34.55 0.985 (0.970–1.001)
<30 54,810 16,669 468,546.87 35.58 1.020 (1.003–1.037)
<40 54,274 17,254 456,174.14 37.82 1.075 (1.057–1.093)
≥40 27,328 9374 223,754.91 41.89 1.146 (1.121–1.171)
6 0– 6 9 years Smoking
None 234,680 120,838 1,658,865.29 72.84 1 (Ref.)
Former 63,700 26,516 483,507.74 54.84 1.043 (1.028–1.057)
Current 62,576 25,584 459,445.93 55.68 1.070 (1.055–1.085)
Smoking Duration
<10 8086 3325 62,011.07 53.62 0.995 (0.961–1.030)
<20 16,114 6629 123,900.78 53.5 1.008 (0.983–1.034)
≥20 102,076 42,146 757,041.83 55.67 1.071 (1.059–1.085)
Smoking Amount
<10 15,304 6349 114,615.22 55.39 1.016 (0.990–1.042)
<20 43,653 17,490 330,843.13 52.86 1.017 (1.000–1.034)
≥20 67,319 28,261 497,495.32 56.81 1.097 (1.082–1.113)
Pack-year
<10 22,502 9291 171,676.93 54.12 1.006 (0.984–1.027)
<20 27,136 10,957 206,175.28 53.14 1.018 (0.998–1.039)
<30 23,692 9655 177,381.99 54.43 1.053 (1.031–1.076)
<40 22,014 8976 165,051.01 54.38 1.064 (1.041–1.087)
≥40 30,932 13,221 222,668.46 59.38 1.146 (1.125–1.168)
≥70 years Smoking
None 115,584 55,053 716,785.13 76.81 1 (Ref.)
Former 26,078 10,862 164,764.43 65.92 1.215 (1.190–1.241)
Current 21,642 8514 129,628.69 65.68 1.209 (1.181–1.237)
Smoking Duration
<10 2504 1046 16,154.30 64.75 1.144 (1.076–1.216)
<20 4459 1846 29,098.07 63.44 1.147 (1.095–1.202)
≥20 40,757 16,484 249,140.75 66.16 1.227 (1.206–1.250)
Smoking Amount
<10 8996 3459 54,624.50 63.32 1.094 (1.057–1.133)
<20 17,637 7105 111,127.01 63.94 1.192 (1.163–1.223)
≥20 21,087 8812 128,641.61 68.5 1.293 (1.263–1.323)
Pack-year
<10 8410 3404 53,411.62 63.73 1.106 (1.068–1.146)
<20 10,023 4033 62,739.92 64.28 1.172 (1.135–1.211)
<30 10,205 4070 63,606.79 63.99 1.212 (1.174–1.252)
<40 6502 2644 40,285.59 65.63 1.232 (1.185–1.281)
≥40 12,580 5225 74,349.19 70.28 1.339 (1.301–1.378)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. IR: incidence rate per 1000 person-years. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Figure A1.

Figure A1

Cumulative incidence of LSS by smoking-related variables, stratified by 10-year age groups. (a) Smoking status; (b) Smoking duration; (c) Smoking amount (cigarettes/day); (d) Pack-year. Cumulative incidence curves were estimated over a 10-year follow-up period for each age group (40–49, 50–59, 60–69, and ≥70 years). Shaded areas represent the range of cumulative incidence curves across smoking subgroups for each age group. Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A2 of Appendix A, which can be cross-referenced for at-risk denominators.

Figure A2.

Figure A2

Hazard ratios (HRs) for LSS by smoking-related variables, stratified by 10-year age groups. (a) Smoking status; (b) Smoking duration; (c) Smoking amount (cigarettes/day); (d) Pack-year. HRs and 95% confidence intervals were derived from the fully adjusted Cox proportional hazards model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. The horizontal dotted line represents HR = 1.0.

Appendix A.3. Detailed Hazard Ratios for LSS by Smoking Exposure Categories, Stratified by Sex

Detailed numerical results of the sex-stratified analysis described in Section 3.2.2 are presented below.

Table A3.

Hazard ratios (HRs) and 95% confidence intervals (CIs) for LSS by smoking-related variables, stratified by sex (Model 4).

Male Female
N Event Duration IR, per 1000 PY Model 4 N Event Duration IR, per 1000 PY Model 4
Smoking
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
Former 328,631 97,404 2,787,349.58 34.945 1.039 (1.030, 1.048) 11,284 4354 89,872.02 48.4467 1.017 (0.987, 1.048)
Current 449,310 119,361 3,865,165.72 30.8812 1.032 (1.024, 1.041) 27,794 12,055 212,270.81 56.7907 1.161 (1.140, 1.183)
Smoking duration
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
<10 62,808 15,751 555,552.11 28.352 0.964 (0.948, 0.981) 12,941 4944 105,039.19 47.0681 1.111 (1.080, 1.143)
<20 168,914 40,989 1,506,248.7 27.2126 0.973 (0.962, 0.984) 13,690 5550 108,613.7 51.0985 1.144 (1.114, 1.175)
≥20 546,219 160,025 4,590,714.5 34.8584 1.061 (1.052, 1.069) 12,447 5915 88,489.95 66.8438 1.105 (1.076, 1.133)
Smoking amount
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
<10 70,864 19,610 598,874.88 32.7447 0.986 (0.971, 1.002) 16,212 6322 128,197.99 49.3143 1.034 (1.009, 1.060)
<20 284,975 75,060 2,471,802.95 30.3665 0.987 (0.978, 0.997) 16,039 6855 123,448.81 55.5291 1.161 (1.134, 1.189)
≥20 422,102 122,095 3,581,837.47 34.0873 1.078 (1.069, 1.087) 6827 3232 50,496.04 64.005 1.223 (1.181, 1.266)
Pack-year
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
<10 167,949 42,010 1,481,513.03 28.3561 0.960 (0.949, 0.971) 26,874 10,563 214,353.66 49.2784 1.091 (1.070, 1.112)
<20 223,442 57,129 1,958,628.77 29.1679 0.987 (0.977, 0.998) 7748 3613 57,037.84 63.3439 1.184 (1.146, 1.224)
<30 191,803 51,456 1,658,332.31 31.0288 1.027 (1.016, 1.038) 2739 1321 19,576.68 67.4782 1.169 (1.107, 1.234)
<40 111,053 35,248 917,426.98 38.4205 1.108 (1.094, 1.121) 1097 594 7261.81 81.7978 1.222 (1.128, 1.325)
≥40 83,694 30,922 636,614.21 48.5726 1.192 (1.177, 1.208) 620 318 3912.85 81.2708 1.030 (0.923, 1.150)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted Cox proportional hazards model (Model 4). Definitions of IR, HR, CI, Model 4, and smoking categories are provided in the footnote of Table 2. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Appendix B

Appendix B.1. Age-Stratified Analysis of Combined Smoking Status and Cumulative Exposure (40–64 vs. ≥65 Years)

This section presents detailed age-stratified results for the combined effect of smoking status (never, former, current) and cumulative exposure (duration, daily amount, pack-years). Hazard ratios (HRs) and incidence rates (IRs) were estimated separately for two age groups (40–64 and ≥65 years), allowing a clearer comparison of risk profiles between middle-aged and older adults. These results supplement the summary provided in Section 3.3.1 and highlight age-related heterogeneity in the association between smoking burden and LSS.

Table A4.

Hazard ratios (HRs) and 95% confidence intervals (CIs) for LSS by combined smoking status and cumulative exposure, stratified by age groups 40–64 and ≥65 years.

Age 40–64 Years Age ≥ 65 Years
N Event Duration IR, per 1000 PY Model 4 N Event Duration IR, per 1000 PY Model 4
Smoking status and Duration
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
Ex and <10 46,560 11,739 416,092.6 28.2125 0.960 (0.942, 0.978) 4171 1749 29,403.59 59.4825 1.078 (1.028, 1.130)
Ex and <20 102,062 25,643 912,671.29 28.0966 0.987 (0.973, 1.000) 8055 3416 56,449.81 60.5139 1.121 (1.083, 1.160)
Ex and ≥20 141,071 43,083 1,208,427.59 35.6521 1.056 (1.044, 1.068) 37,996 16,128 254,176.73 63.4519 1.162 (1.142, 1.182)
Current and <10 23,852 6707 207,405.74 32.3376 1.048 (1.023, 1.074) 1166 500 7689.36 65.0249 1.122 (1.028, 1.226)
Current and <20 70,728 16,727 633,893.58 26.3877 0.988 (0.972, 1.004) 1759 753 11,847.72 63.5565 1.083 (1.008, 1.164)
Current and ≥20 337,748 89,686 2,945,842.71 30.4449 1.036 (1.027, 1.045) 41,851 17,043 270,757.42 62.9456 1.181 (1.162, 1.201)
Smoking status and Amount
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
Ex and <10 33,869 9208 298,378.64 30.8601 0.976 (0.955, 0.996) 6796 2819 46,961.44 60.028 1.069 (1.030, 1.110)
Ex and <20 111,522 29,025 990,516.61 29.3029 0.976 (0.963, 0.988) 16,595 6948 114,740 60.5543 1.111 (1.084, 1.139)
Ex and ≥20 144,302 42,232 1,248,296.22 33.8317 1.063 (1.051, 1.075) 26,831 11,526 178,328.69 64.6335 1.196 (1.172, 1.220)
Current and <10 37,569 10,432 326,318.06 31.9688 1.012 (0.992, 1.032) 8842 3473 55,414.73 62.6729 1.046 (1.011, 1.082)
Current and <20 155,360 38,848 1,375,079.36 28.2515 0.989 (0.977, 1.000) 17,537 7094 114,915.78 61.7322 1.158 (1.130, 1.186)
Current and ≥20 239,399 63,840 2,085,744.6 30.6078 1.063 (1.052, 1.073) 18,397 7729 119,964.01 64.4277 1.267 (1.238, 1.298)
Smoking status and Pack-year
None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
Ex and <10 101,770 25,723 909,312.8 28.2884 0.963 (0.950, 0.976) 10,918 4602 76,293.27 60.3199 1.093 (1.061, 1.126)
Ex and <20 88,423 23,332 782,979.37 29.799 1.000 (0.986, 1.014) 11,374 4763 78,841.49 60.4124 1.118 (1.086, 1.151)
Ex and ≥20 99,500 31,410 844,899.3 37.176 1.091 (1.077, 1.105) 27,930 11,928 184,895.37 64.5122 1.187 (1.164, 1.210)
Current and <10 76,514 19,894 674,145.96 29.5099 1.003 (0.988, 1.017) 5621 2354 36,114.67 65.1813 1.070 (1.027, 1.114)
Current and <20 122,774 29,195 1,097,919.01 26.5912 0.985 (0.973, 0.998) 8619 3452 55,926.74 61.7236 1.114 (1.077, 1.153)
Current and ≥20 233,040 64,031 2,015,077.06 31.776 1.064 (1.054, 1.075) 30,536 12,490 198,253.1 63.0003 1.220 (1.196, 1.243)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted model (Model 4). Definitions of IR, HR, CI, Model 4, and reference group are provided in the footnote of Table 2. Smoking duration categories: <10, <20, ≥20 years; smoking amount: <10, <20, ≥20 cigarettes/day; pack-year: <10, <20, ≥20 pack-years. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Appendix B.2. Association Between Smoking Burden and LSS by 10-Year Age Bands

This appendix provides extended age-stratified results using 10-year age bands (40–49, 50–59, 60–69, and ≥70 years), complementing the main findings reported in Section 3.3.1. Hazard ratios were estimated for each subgroup by smoking status and cumulative exposure, including duration, amount, and pack-years. The results demonstrate a progressive increase in risk with advancing age and higher smoking burden.

  • Age 40–49: Significant risk was observed among current smokers with ≥20 years (HR 1.037), ≥20 cigarettes/day (HR 1.057), or ≥20 pack-years (HR 1.092). Among former smokers, only those with ≥20 pack-years showed increased risk (HR 1.058).

  • Age 50–59: Risk was significantly elevated across most high-exposure categories. Former smokers with ≥20 pack-years had HR 1.102, while current smokers had HR 1.066.

  • Age 60–69: Consistent risk elevation was seen in nearly all subgroups. The HR for former smokers with ≥20 pack-years (HR 1.139) slightly exceeded that of current smokers (HR 1.092).

  • Age ≥ 70: This group exhibited the highest and most consistent risk. Current smokers with ≥20 years of smoking (HR 1.220), ≥20 cigarettes/day (HR 1.289), and ≥20 pack-years (HR 1.231) showed substantial increases, highlighting the amplified harm of continued smoking in older adults.

Table A5.

Hazard ratios (HRs) and 95% confidence intervals (CIs) for LSS by combined smoking status and cumulative exposure, stratified by 10-year age bands (40–49, 50–59, 60–69, and ≥70 years).

Age
Group
Category N Events Duration
(PY)
IR
(per 1000 PY)
Model 4 HR
(95% CI)
40–49 years Smoking status and Duration
None 544,195 148,119 4,834,353.75 30.6388 1 (Ref.)
Ex and <10 27,747 5762 255,757.17 22.5292 0.981 (0.956, 1.008)
Ex and <20 61,787 12,800 570,044.06 22.4544 1.014 (0.995, 1.033)
Ex and ≥20 47,760 10,836 435,473.06 24.8833 1.071 (1.050, 1.093)
Current and <10 15,343 3668 138,058.69 26.5684 1.067 (1.032, 1.102)
Current and <20 53,329 10,854 489,572.35 22.1704 0.998 (0.978, 1.018)
Current and ≥20 177,925 37,421 1,626,795.59 23.0029 1.037 (1.024, 1.050)
Smoking status and amount
None 544,195 148,119 4,834,353.75 30.6388 1 (Ref.)
Ex and <10 17,126 3718 156,889.87 23.6982 1.005 (0.972, 1.038)
Ex and <20 56,432 11,515 522,206.31 22.0507 0.992 (0.973, 1.012)
Ex and ≥20 63,736 14,165 582,178.11 24.331 1.069 (1.050, 1.088)
Current and <10 21,523 4818 195,612.48 24.6303 1.016 (0.987, 1.046)
Current and <20 91,225 18,535 839,127.79 22.0884 1.002 (0.986, 1.018)
Current and ≥20 133,849 28,590 1,219,686.35 23.4405 1.057 (1.043, 1.072)
Smoking status and Pack-year
None 544,195 148,119 4,834,353.75 30.6388 1 (Ref.)
Ex and <10 58,208 11,917 537,933.86 22.1533 0.984 (0.966, 1.004)
Ex and <20 46,003 9721 423,526.72 22.9525 1.032 (1.010, 1.054)
Ex and ≥20 33,083 7760 299,813.71 25.8827 1.107 (1.081, 1.133)
Current and <10 50,274 10,887 458,211.87 23.7598 1.013 (0.993, 1.034)
Current and <20 80,737 16,045 744,722.58 21.5449 0.998 (0.981, 1.015)
Current and ≥20 115,586 25,011 1,051,492.19 23.7862 1.068 (1.052, 1.083)
5 0– 5 9 years Smoking status and Duration
None 411,790 164,725 3,317,386.08 49.6551 1 (Ref.)
Ex and <10 14,921 4432 129,554.59 34.2095 0.943 (0.915, 0.972)
Ex and <20 31,969 9569 276,704.22 34.5821 0.974 (0.953, 0.994)
Ex and ≥20 65,953 20,981 561,416.34 37.3716 1.038 (1.022, 1.054)
Current and <10 7148 2462 59,055.47 41.6896 1.052 (1.011, 1.095)
Current and <20 14,946 4841 125,542.93 38.5605 1.014 (0.985, 1.044)
Current and ≥20 124,195 38,072 1,049,336.88 36.282 1.035 (1.022, 1.047)
Smoking status and amount
None 411,790 164,725 3,317,386.08 49.6551 1 (Ref.)
Ex and <10 12,154 3662 105,270 34.7867 0.945 (0.915, 0.977)
Ex and <20 41,873 12,302 363,566.82 33.837 0.959 (0.941, 0.978)
Ex and ≥20 58,816 19,018 498,838.33 38.1246 1.057 (1.040, 1.074)
Current and <10 11,973 3926 100,060.79 39.2361 1.006 (0.975, 1.039)
Current and <20 50,194 14,968 428,380.7 34.9409 0.986 (0.969, 1.004)
Current and ≥20 84,122 26,481 705,493.79 37.5354 1.070 (1.055, 1.085)
Smoking status and Pack-year
None 411,790 164,725 3,317,386.08 49.6551 1 (Ref.)
Ex and <10 33,881 10,031 294,240.46 34.0912 0.952 (0.932, 0.971)
Ex and <20 32,561 9691 281,697.45 34.4022 0.976 (0.956, 0.997)
Ex and ≥20 46,401 15,260 391,737.24 38.9547 1.075 (1.057, 1.094)
Current and <10 21,548 7043 180,391.94 39.0428 1.009 (0.985, 1.034)
Current and <20 34,730 10,295 296,804.67 34.6861 0.992 (0.972, 1.013)
Current and ≥20 90,011 28,037 756,738.68 37.0498 1.060 (1.046, 1.075)
6 0– 6 9 years Smoking status and Duration
None 234,680 120,838 1,658,865.29 72.8438 1 (Ref.)
Ex and <10 6032 2445 46,865.45 52.1706 0.983 (0.944, 1.023)
Ex and <20 12,568 5109 97,522.43 52.3879 1.006 (0.977, 1.035)
Ex and ≥20 45,100 18,962 339,119.86 55.9153 1.064 (1.047, 1.081)
Current and <10 2054 880 15,145.61 58.1026 1.029 (0.963, 1.099)
Current and <20 3546 1520 26,378.35 57.623 1.013 (0.963, 1.066)
Current and ≥20 56,976 23,184 417,921.97 55.4745 1.077 (1.061, 1.093)
Smoking status and amount
None 234,680 120,838 1,658,865.29 72.8438 1 (Ref.)
Ex and <10 7810 3213 60,146.81 53.4193 0.997 (0.963, 1.033)
Ex and <20 20,993 8507 162,021.57 52.5054 1.010 (0.987, 1.033)
Ex and ≥20 34,897 14,796 261,339.37 56.616 1.079 (1.060, 1.098)
Current and <10 7494 3136 54,468.42 57.5746 1.035 (0.999, 1.073)
Current and <20 22,660 8983 168,821.56 53.21 1.024 (1.001, 1.046)
Current and ≥20 32,422 13,465 236,155.95 57.0174 1.118 (1.098, 1.139)
Smoking status and Pack-year
None 234,680 120,838 1,658,865.29 72.8438 1 (Ref.)
Ex and <10 15,106 6126 117,395.9 52.1824 0.992 (0.966, 1.018)
Ex and <20 15,537 6298 119,705.7 52.6124 1.013 (0.987, 1.040)
Ex and ≥20 33,057 14,092 246,406.15 57.1901 1.088 (1.068, 1.108)
Current and <10 7396 3165 54,281.03 58.3077 1.032 (0.996, 1.069)
Current and <20 11,599 4659 86,469.59 53.8802 1.024 (0.994, 1.055)
Current and ≥20 43,581 17,760 318,695.31 55.7272 1.095 (1.077, 1.114)
≥70 years Smoking status and Duration
None 115,584 55,053 716,785.13 76.8054 1 (Ref.)
Ex and <10 2031 849 13,318.97 63.7437 1.143 (1.068, 1.224)
Ex and <20 3793 1581 24,850.39 63.6207 1.173 (1.115, 1.233)
Ex and ≥20 20,254 8432 126,595.06 66.6061 1.234 (1.205, 1.263)
Current and <10 473 197 2835.33 69.4805 1.142 (0.993, 1.314)
Current and <20 666 265 4247.67 62.3871 1.010 (0.896, 1.140)
Current and ≥20 20,503 8052 122,545.68 65.7061 1.220 (1.191, 1.249)
Smoking status and amount
None 115,584 55,053 716,785.13 76.8054 1 (Ref.)
Ex and <10 3575 1434 23,033.41 62.2574 1.107 (1.050, 1.167)
Ex and <20 8819 3649 57,461.92 63.5029 1.177 (1.138, 1.218)
Ex and ≥20 13,684 5779 84,269.1 68.5779 1.279 (1.244, 1.315)
Current and <10 5421 2025 31,591.1 64.1003 1.086 (1.038, 1.135)
Current and <20 8818 3456 53,665.08 64.3994 1.208 (1.167, 1.250)
Current and ≥20 7403 3033 44,372.51 68.3531 1.319 (1.271, 1.368)
Smoking status and Pack-year
None 115,584 55,053 716,785.13 76.8054 1 (Ref.)
Ex and <10 5493 2251 36,035.84 62.4656 1.129 (1.082, 1.177)
Ex and <20 5696 2385 36,891 64.6499 1.197 (1.149, 1.248)
Ex and ≥20 14,889 6226 91,837.59 67.7936 1.265 (1.232, 1.299)
Current and <10 2917 1153 17,375.78 66.3567 1.065 (1.004, 1.129)
Current and <20 4327 1648 25,848.92 63.7551 1.137 (1.082, 1.194)
Current and ≥20 14,398 5713 86,403.98 66.1196 1.272 (1.237, 1.308)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted Cox proportional hazards model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. IR: incidence rate per 1000 person-years, calculated as the number of events divided by total follow-up time. Non-smokers served as the reference group (Ref.) in each exposure category. Smoking duration was categorized as <10, <20, and ≥20 years; smoking amount as <10, <20, and ≥20 cigarettes/day; and pack-year as <10, <20, and ≥20 pack-years. Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Figure A3.

Figure A3

Cumulative incidence of LSS over a 10-year follow-up period by combined smoking status and exposure level across 10-year age bands. (a) Smoking duration; (b) Smoking amount (cigarettes/day); (c) Pack-year. Curves are stratified by age group (40–49, 50–59, 60–69, ≥70 years) and further divided into former (Ex) and current smokers. Non-smokers served as the reference group and are not displayed for visual clarity. Exposure subgroups are defined as <10, <20, and ≥20 years for smoking duration; <10, <20, and ≥20 cigarettes/day for smoking amount; and <10, <20, <30, <40, and ≥40 pack-years for pack-year Note: Numbers at risk at standard time points could not be displayed beneath the curves due to the use of aggregated summary-level data. Instead, group-specific participant numbers and events are provided in Table A5 of Appendix B, which can be cross-referenced for at-risk denominators.

Figure A4.

Figure A4

Hazard ratios (HRs) with 95% confidence intervals for LSS by combined smoking status and exposure level across 10-year age bands (Model 4). (a) Smoking duration; (b) Smoking amount (cigarettes/day); (c) Pack-year. Bars are grouped by age (40–49, 50–59, 60–69, ≥70 years) and arranged by exposure subgroup, with former (Ex) on the left and current on the right separated by a vertical dashed divider. The horizontal dashed line indicates HR = 1.0. Non-smokers served as the reference (HR = 1.0) and are not displayed for visual clarity. HRs were estimated from the fully adjusted Cox model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia.

Appendix B.3. Sex-Stratified Association Between Combined Smoking Burden and LSS Risk

This section presents detailed numerical estimates for the sex-stratified analysis described in Section 3.3.2. The results illustrate marked differences between men and women in the association between smoking burden and the risk of developing LSS. In men, a history of prolonged and heavy smoking was associated with sustained elevated risk, even after cessation. Conversely, in women, current smoking was the dominant risk factor, with former smoking generally showing limited or no significant association. These findings suggest differing biological vulnerability and cessation-related reversibility between sexes. Full model-adjusted hazard ratios (Model 4) are provided in Table A6, with corresponding visualizations in the main text (Figure 12 and Figure 13).

Table A6.

Sex-stratified hazard ratios for LSS according to combined smoking cessation status and cumulative exposure (Model 4).

Male Female
N Event Duration IR, per 1000 PY Model 4 N Event Duration IR, per 1000 PY Model 4
Smoking status and Duration
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
Ex and <10 44,935 11,429 397,632.64 28.7426 0.960 (0.942, 0.979) 5796 2059 47,863.55 43.0181 1.014 (0.971, 1.059)
Ex and <20 106,652 27,717 941,295.46 29.4456 0.993 (0.980, 1.006) 3465 1342 27,825.64 48.2289 1.038 (0.984, 1.095)
Ex and ≥20 177,044 58,258 1,448,421.49 40.2217 1.080 (1.069, 1.091) 2023 953 14,182.83 67.1939 0.995 (0.934, 1.061)
Current and <10 17,873 4322 157,919.47 27.3684 0.973 (0.944, 1.003) 7145 2885 57,175.63 50.4586 1.191 (1.148, 1.235)
Current and <20 62,262 13,272 564,953.24 23.4922 0.931 (0.914, 0.948) 10,225 4208 80,788.06 52.0869 1.182 (1.147, 1.219)
Current and ≥20 369,175 101,767 3,142,293.01 32.3862 1.049 (1.040, 1.059) 10,424 4962 74,307.12 66.7769 1.129 (1.097, 1.161)
Smoking status and amount
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
Ex and <10 35,010 9971 299,350.64 33.3088 0.989 (0.969, 1.010) 5655 2056 45,989.44 44.7059 0.979 (0.937, 1.022)
Ex and <20 124,059 34,380 1,072,986.15 32.0414 0.992 (0.979, 1.004) 4058 1593 32,270.46 49.364 1.039 (0.989, 1.092)
Ex and ≥20 169,562 53,053 1,415,012.78 37.4929 1.084 (1.072, 1.095) 1571 705 11,612.12 60.7124 1.091 (1.013, 1.174)
Current and <10 35,854 9639 299,524.24 32.181 0.984 (0.963, 1.005) 10,557 4266 82,208.55 51.8924 1.063 (1.032, 1.096)
Current and <20 160,916 40,680 1,398,816.79 29.0817 0.983 (0.972, 0.995) 11,981 5262 91,178.35 57.7111 1.204 (1.172, 1.237)
Current and ≥20 252,540 69,042 2,166,824.69 31.8632 1.073 (1.063, 1.084) 5256 2527 38,883.92 64.9883 1.266 (1.217, 1.316)
Smoking status and Pack-year
None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
Ex and <10 103,602 26,995 911,509.23 29.6157 0.970 (0.957, 0.983) 9086 3330 74,096.83 44.9412 1.004 (0.970, 1.039)
Ex and <20 98,397 27,458 851,443.59 32.2488 1.009 (0.996, 1.023) 1400 637 10,377.28 61.3841 1.097 (1.015, 1.186)
Ex and ≥20 126,632 42,951 1,024,396.76 41.9281 1.109 (1.097, 1.122) 798 387 5397.92 71.6943 1.006 (0.911, 1.112)
Current and <10 64,347 15,015 570,003.8 26.3419 0.947 (0.930, 0.963) 17,788 7233 140,256.82 51.5697 1.137 (1.111, 1.164)
Current and <20 125,045 29,671 1,107,185.19 26.7986 0.970 (0.957, 0.983) 6348 2976 46,660.57 63.7798 1.204 (1.161, 1.248)
Current and ≥20 259,918 74,675 2,187,976.73 34.1297 1.079 (1.069, 1.090) 3658 1846 25,353.42 72.8107 1.195 (1.142, 1.251)

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the fully adjusted model (Model 4). Definitions of IR, HR, CI, Model 4, and reference group are provided in the footnote of Table 2. Smoking duration categories: <10, <20, ≥20 years; smoking amount: <10, <20, ≥20 cigarettes/day; pack-year: <10, <20, ≥20 pack-years. Results are stratified by sex (male, female). Incidence rates are crude (unadjusted), presented per 1000 person-years. Incident LSS was defined as ≥3 M48.06 claims on distinct service dates (outpatient or inpatient; same-day duplicates counted once; same provider not required); index date = date of the third claim.

Appendix C

Appendix C.1. Subgroup and Interaction Analyses for Smoking-Related Risk of LSS

This appendix provides detailed subgroup-specific hazard ratios and p-values for interaction terms that examine whether the association between smoking and LSS differed across demographic and clinical subpopulations. As described in Section 3.4, significant effect modifications were observed for age and sex, with higher relative risks seen in women and older adults. Other modifiers such as income, obesity, hypertension, alcohol use, and exercise habits also influenced the strength of association. The full results are presented in Table A7. Visual summaries are provided in the main text (Figure 14), including both the original and sorted views of subgroup hazard ratios for current smokers.

Table A7.

Subgroup and interaction analyses of the association between smoking and risk of LSS (Model 4).

Smoking N Event Duration IR, per 1000 PY HR (95% C.I) p for Interaction
Age groups 40–64 None 1,099,107 384,974 9,190,028.6 41.8904 1 (Ref.) <0.0001
Former 289,693 80,465 2,537,191.47 31.7142 1.016 (1.007, 1.025)
Current 432,328 113,120 3,787,142.02 29.8695 1.027 (1.019, 1.036)
≥65 None 207,142 103,761 1,337,361.64 77.5863 1 (Ref.)
Former 50,222 21,293 340,030.13 62.6209 1.146 (1.129, 1.164)
Current 44,776 18,296 290,294.51 63.0256 1.174 (1.155, 1.193)
Sex Male None 357,217 104,334 3,007,774.09 34.6881 1 (Ref.) <0.0001
Former 328,631 97,404 2,787,349.58 34.945 1.039 (1.030, 1.048)
Current 449,310 119,361 3,865,165.72 30.8812 1.032 (1.024, 1.041)
Female None 949,032 384,401 7,519,616.15 51.1198 1 (Ref.)
Former 11,284 4354 89,872.02 48.4467 1.017 (0.987, 1.048)
Current 27,794 12,055 212,270.81 56.7907 1.161 (1.140, 1.183)
Income Q2–4 None 1,012,450 372,930 8,188,085.61 45.5454 1 (Ref.) 0.0005
Former 289,948 84,875 2,471,224.75 34.3453 1.051 (1.042, 1.060)
Current 389,716 104,906 3,356,176.65 31.2576 1.058 (1.049, 1.067)
Q1 None 293,799 115,805 2,339,304.63 49.504 1 (Ref.)
Former 49,967 16,883 405,996.85 41.5841 1.032 (1.015, 1.050)
Current 87,388 26,510 721,259.88 36.7551 1.029 (1.015, 1.044)
Obesity BMI ≥ 25 No None 888,363 311,645 7,285,125.45 42.7783 1 (Ref.) <0.0001
Former 201,186 57,927 1,706,108.62 33.9527 1.064 (1.053, 1.075)
Current 315,768 85,234 2,690,884.35 31.6751 1.084 (1.074, 1.094)
Yes None 417,886 177,090 3,242,264.79 54.6192 1 (Ref.)
Former 138,729 43,831 1,171,112.99 37.4268 1.023 (1.011, 1.035)
Current 161,336 46,182 1,386,552.18 33.3071 0.997 (0.986, 1.009)
Abdominal obesity WC ≥ 90/85 No None 1,050,019 373,418 8,611,942.99 43.3605 1 (Ref.) <0.0001
Former 254,634 72,921 2,176,702.42 33.5007 1.050 (1.040, 1.059)
Current 375,478 100,325 3,224,739.94 31.111 1.061 (1.052, 1.071)
Yes None 256,230 115,317 1,915,447.25 60.2037 1 (Ref.)
Former 85,281 28,837 700,519.18 41.1652 1.039 (1.025, 1.054)
Current 101,626 31,091 852,696.59 36.462 1.020 (1.006, 1.033)
Heavy Drinking No None 1,274,037 477,654 10,263,653.04 46.5384 1 (Ref.) <0.0001
Former 294,203 87,686 2,489,838.14 35.2176 1.052 (1.043, 1.062)
Current 388,734 106,440 3,328,505.56 31.9783 1.057 (1.049, 1.066)
Yes None 32,212 11,081 263,737.2 42.0153 1 (Ref.)
Former 45,712 14,072 387,383.46 36.3258 0.998 (0.974, 1.023)
Current 88,370 24,976 748,930.97 33.3489 1.004 (0.982, 1.027)
Regular exercise No None 1,056,687 394,391 8,510,009.22 46.3444 1 (Ref.) 0.0006
Former 247,026 73,379 2,091,526.47 35.0839 1.055 (1.046, 1.065)
Current 390,873 106,624 3,346,129.42 31.8649 1.052 (1.043, 1.060)
Yes None 249,562 94,344 2,017,381.02 46.7656 1 (Ref.)
Former 92,889 28,379 785,695.13 36.1196 1.025 (1.011, 1.040)
Current 86,231 24,792 731,307.12 33.9009 1.055 (1.039, 1.070)
Diabetes mellitus No None 1,182,850 436,748 9,617,386.13 45.4123 1 (Ref.) 0.6053
Former 293,360 86,456 2,504,674.67 34.5179 1.047 (1.038, 1.056)
Current 414,622 112,825 3,571,551.9 31.5899 1.051 (1.042, 1.059)
Yes None 123,399 51,987 910,004.11 57.1283 1 (Ref.)
Former 46,555 15,302 372,546.93 41.074 1.050 (1.031, 1.070)
Current 62,482 18,591 505,884.64 36.7495 1.060 (1.042, 1.079)
Hypertension No None 915,672 320,598 7,602,004.07 42.1728 1 (Ref.) <0.0001
Former 214,932 60,003 1,865,175.94 32.1702 1.039 (1.029, 1.050)
Current 336,565 88,176 2,931,440.05 30.0794 1.043 (1.033, 1.052)
Yes None 390,577 168,137 2,925,386.18 57.4751 1 (Ref.)
Former 124,983 41,755 1,012,045.67 41.258 1.059 (1.047, 1.072)
Current 140,539 43,240 1,145,996.49 37.7314 1.071 (1.058, 1.083)
Dyslipidemia No None 1,029,585 368,292 8,421,523.44 43.7322 1 (Ref.) 0.9503
Former 263,858 77,121 2,247,188.26 34.3189 1.048 (1.038, 1.058)
Current 383,004 103,183 3,287,469.18 31.3868 1.052 (1.043, 1.061)
Yes None 276,664 120,443 2,105,866.8 57.194 1 (Ref.)
Former 76,057 24,637 630,033.34 39.1043 1.045 (1.030, 1.061)
Current 94,100 28,233 789,967.36 35.7395 1.052 (1.037, 1.066)

HRs were derived from the fully adjusted Cox proportional hazards model (Model 4), adjusting for age, sex, body mass index, income level, alcohol consumption, regular exercise, diabetes mellitus, hypertension, and dyslipidemia. p for interaction was calculated to assess whether the association between smoking and LSS differed significantly across subgroups. P for interaction values were derived from multiplicative interaction terms in the Cox proportional hazards models.

Appendix D

Standardized Mean Differences (SMDs) for Baseline Characteristics

To supplement Table 1, we present standardized mean differences (SMDs) between smoking status groups (never, former, and current smokers). SMDs were calculated for continuous variables as the mean difference between groups divided by the pooled standard deviation. An absolute SMD greater than 0.1 was considered indicative of meaningful imbalance between groups.

Table A8.

Standardized mean differences (SMDs) for baseline characteristics among smoking groups.

Non vs. Former Non vs. Current Former vs. Current
Age, years 0.00 0.25 0.27
Height, cm −1.13 −1.18 −0.06
Weight, kg −0.92 −0.72 0.18
BMI, kg/m 2 −0.21 −0.01 0.2
Waist Circumference, cm −0.66 −0.49 0.18
Systolic BP, mmHg −0.21 −0.11 0.10
Diastolic BP, mmHg −0.26 −0.2 0.06
Fasting glucose, mg/dL −0.19 −0.17 0.01
Total Cholesterol, mg/dL 0.02 0.01 −0.02
HDL-C, mg/dL 0.13 0.15 0.02
LDL-C, mg/dL 0.08 0.14 0.06
Triglyceride, mg/dL −0.21 −0.31 −0.09

Values represent standardized mean differences (SMDs) between smoking status groups. An absolute SMD > 0.1 indicates a potentially meaningful imbalance. Abbreviations: BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Author Contributions

Data curation: J.-H.R. and J.-Y.K.; Formal analysis J.-H.R. and J.-Y.K.; Conceptualization: K.-W.K. and J.-Y.K.; Writing—original draft: J.-H.R. and J.-Y.K.; Writing—review and editing: K.-W.K. and J.-Y.K. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Yeouido St. Mary’s Hospital (SC23Z ISI0055, 28 April 2023).

Informed Consent Statement

Informed consent is not required for this type of study.

Data Availability Statement

All data concerning the case are presented in the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

Authors received research funding from IL-YANG Pharm. Co., Ltd. for the conduct of the present work (GNUCH 2025-09-011).

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Rhon D. Lumbar Spinal Stenosis (Correspondence) N. Engl. J. Med. 2008;358:2647–2648. doi: 10.1056/NEJMc080600. [DOI] [PubMed] [Google Scholar]
  • 2.Walter K.L., O’Toole J.E. Lumbar Spinal Stenosis (JAMA Patient Page) JAMA. 2022;328:310. doi: 10.1001/jama.2022.6137. [DOI] [PubMed] [Google Scholar]
  • 3.Myllykangas H., Ristolainen L., Hurri H., Lohikoski J., Kautiainen H., Puisto V., Österman H., Manninen M. Obese people benefit from lumbar LSS surgery as much as people of normal weight. J. Orthop. Surg. Res. 2021;16:550. doi: 10.1186/s13018-021-02692-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Giri B., Singh D.B., Chattu V.K. Aging population in South Korea: Burden or opportunity? IJS Glob. Health. 2024;7:e00517. doi: 10.1097/GH9.0000000000000517. [DOI] [Google Scholar]
  • 5.Ryu J.H., Han K., Kim J.Y. Association Between Higher Body Mass Index and the Risk of Lumbar LSS in Korean Populations: A Nationwide Cohort Study. J. Clin. Med. 2024;13:7397. doi: 10.3390/jcm13237397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Amin S., Niu J., Guermazi A., Grigoryan M., Hunter D.J., Clancy M., LaValley M.P., Genant H.K., Felson D.T. Cigarette smoking and the risk for cartilage loss and knee pain in men with knee osteoarthritis. Ann. Rheum. Dis. 2007;66:18–22. doi: 10.1136/ard.2006.056697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bagley C., MacAllister M., Dosselman L., Moreno J., Aoun S.G., El Ahmadieh T.Y. Current concepts and recent advances in understanding and managing lumbar spine stenosis. F1000Research. 2019;8:137. doi: 10.12688/f1000research.16082.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Elmasry S., Asfour S., de Rivero Vaccari J.P., Travascio F. Effects of Tobacco Smoking on the Degeneration of the Intervertebral Disc: A Finite Element Study. PLoS ONE. 2015;10:e0136137. doi: 10.1371/journal.pone.0136137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.De Geer C.M. Intervertebral Disk Nutrients and Transport Mechanisms in Relation to Disk Degeneration: A Narrative Literature Review. J. Chiropr. Med. 2018;17:97–105. doi: 10.1016/j.jcm.2017.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shiri R., Karppinen J., Leino-Arjas P., Solovieva S., Viikari-Juntura E. The association between smoking and low back pain: A meta-analysis. Am. J. Med. 2010;123:87.e7–87.e35. doi: 10.1016/j.amjmed.2009.05.028. [DOI] [PubMed] [Google Scholar]
  • 11.Deng G.H. Causal relationship between smoking and LSS: Two-sample Mendelian randomization. Medicine. 2024;103:e39783. doi: 10.1097/MD.0000000000039783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rajesh N., Moudgil-Joshi J., Kaliaperumal C. Smoking and degenerative spinal disease: A systematic review. Brain Spine. 2022;2:100916. doi: 10.1016/j.bas.2022.100916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Khurana V.G. Adverse impact of smoking on the spine and spinal surgery. Surg. Neurol. Int. 2021;12:118. doi: 10.25259/SNI_6_2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Park S.E., Seo M.H., Cho J.-H., Kwon H., Kim Y.-H., Han K.-D., Jung J.-H., Park Y.-G., Rhee E.-J., Lee W.-Y. Dose-Dependent Effect of Smoking on Risk of Diabetes Remains after Smoking Cessation: A Nationwide Population-Based Cohort Study in Korea. Diabetes Metab. J. 2021;45:539–546. doi: 10.4093/dmj.2020.0061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kim S.K., Kim H.C., Shim J.-S., Kim D.J. Effects of cigarette smoking on blood lipids in Korean men: Cardiovascular and Metabolic Diseases Etiology Research Center cohort. Korean J. Intern. Med. 2020;35:369–382. doi: 10.3904/kjim.2019.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Uei H., Matsuzaki H., Oda H., Nakajima S., Tokuhashi Y., Esumi M. Gene expression changes in an early stage of intervertebral disc degeneration induced by passive cigarette smoking. Spine. 2006;31:510–514. doi: 10.1097/01.brs.0000201304.81875.cc. [DOI] [PubMed] [Google Scholar]
  • 17.Bradford S.T., Stamatovic S.M., Dondeti R.S., Keep R.F., Andjelkovic A.V. Nicotine aggravates the brain postischemic inflammatory response. Am. J. Physiol. Heart Circ. Physiol. 2011;300:H1518–H1529. doi: 10.1152/ajpheart.00928.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fagerström K. The epidemiology of smoking: Health consequences and benefits of cessation. Drugs. 2002;62((Suppl. S2)):1–9. doi: 10.2165/00003495-200262002-00001. [DOI] [PubMed] [Google Scholar]
  • 19.Khullar D., Maa J. The impact of smoking on surgical outcomes. J. Am. Coll. Surg. 2012;215:418–426. doi: 10.1016/j.jamcollsurg.2012.05.023. [DOI] [PubMed] [Google Scholar]
  • 20.Oh K., Kim Y., Kweon S., Kim S., Yun S., Park S., Lee Y.K., Kim Y., Park O., Jeong E.K. Korea National Health and Nutrition Examination Survey, 20th anniversary: Accomplishments and future directions. Epidemiol. Health. 2021;43:e2021025. doi: 10.4178/epih.e2021025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ward K.D., Klesges R.C. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif. Tissue Int. 2001;68:259–270. doi: 10.1007/BF02390832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kim S.Y., Yang M.-Y., Salo S., Sund R., Sirola J., Kröger H., Yoo H., Kang M.-Y. Occupational risk factors for lumbar spinal stenosis: A systematic review. Occup. Med. 2025;75:91–98. doi: 10.1093/occmed/kqaf005. [DOI] [PubMed] [Google Scholar]
  • 23.Lou C., Chen H., Mei L., Yu W., Zhu K., Liu F., Chen Z., Xiang G., Chen M., Weng Q., et al. Association between menopause and lumbar disc degeneration: An MRI study of 1566 women and 1382 men. Menopause. 2017;24:1279–1284. doi: 10.1097/GME.0000000000000902. [DOI] [PubMed] [Google Scholar]
  • 24.Ahn J., Park H.-S., Cho S.J., Baek S., Rhee Y., Hong N. Association of secondhand smoke with fracture risk in community-dwelling nonsmoking adults in Korea. JBMR Plus. 2024;8:ziae010. doi: 10.1093/jbmrpl/ziae010. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data concerning the case are presented in the manuscript.


Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES